Vernon Sondak, MD

New treatments for adults and children with melanoma and other cutaneous malignancies, with particular emphasis on preoperative (neoadjuvant) therapy approaches and on the prediction of nodal metastasis in clinically localized melanoma.

Associations

• Cutaneous Oncology
• Individualized Cancer Management
• Immuno-Oncology Program
• Melanoma & Skin Cancer Center of Excellence

Education & Training

Internship:

• UCLA School of Medicine, Los Angeles, CA - Resident - General Surgery

Board Certification:

Fellowship:

• UCLA School of Medicine, Los Angeles, CA - Surgical Oncology

Residency:

• UCLA School of Medicine, Los Angeles, CA - General Surgery
• UCLA School of Medicine, Los Angeles, CA - General Surgery

Medical School:

• Boston University School of Medicine, Boston, MA

Dr. Sondak has been a leader in studies of surgical treatment of melanoma and other cutaneous malignancies, particularly the application of sentinel lymph node biopsy and lymph node dissection to the staging and treatment of melanoma, and has been instrumental in mentoring and training many surgeons in these techniques over the years. His research interests include surgical treatment of melanoma in adults and children; adjuvant (postoperative) and neoadjuvant (preoperative) therapy of melanoma; and evaluation of new therapies for localized or disseminated melanoma.

Clinical Trial 21125
MElanoma Research Lymph Node Prediction Implementation National_001 (MERLIN_001)
Condition: Cutaneous
Status: Open

Clinical Trial 22566
Creation of Patient-Derived Xenografts from Early-Stage Primary Cutaneous Melanomas
Condition: Cutaneous
Status: Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

• Sondak VK, Atkins MB, Messersmith H, Provenzano A, Seth R, Agarwala SS. Systemic Therapy for Melanoma: ASCO Guideline Update Q and A. JCO Oncol Pract. 2024 Feb.20(2):173-177. Pubmedid: 38039436.
• Mendelson K, Martin TC, Nguyen CB, Hsu M, Xu J, Lang CC, Dummer R, Saenger Y, Messina JL, Sondak VK, Desman G, Hasson D, Bernstein E, Parsons RE, Celebi JT. Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation. JCI Insight. 2024 Feb.9(6). Pubmedid: 38319712.
• Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 Oct.41(30):4794-4820. Pubmedid: 37579248.
• Zhao Y, Amorrortu RP, Stewart SC, Ghia KM, Williams VL, Sondak VK, Tsai KY, Pinilla-Ibarz J, Chavez JC, Rollison DE. Melanoma and CLL co-occurrence and survival: role of KC history. BMC Cancer. 2023 Nov.23(1):1084. Pubmedid: 37946198. Pmcid: PMC10636833.
• Kashani-Sabet M, Leachman SA, Stein JA, Arbiser JL, Berry EG, Celebi JT, Curiel-Lewandrowski C, Ferris LK, Grant-Kels JM, Grossman D, Kulkarni RP, Marchetti MA, Nelson KC, Polsky D, Seiverling EV, Swetter SM, Tsao H, Verdieck-Devlaeminck A, Wei ML, Bar A, Bartlett EK, Bolognia JL, Bowles TL, Cha KB, Chu EY, Hartman RI, Hawryluk EB, Jampel RM, Karapetyan L, Kheterpal M, Lawson DH, Leming PD, Liebman TN, Ming ME, Sahni D, Savory SA, Shaikh SS, Sober AJ, Sondak VK, Spaccarelli N, Usatine RP, Venna S, Kirkwood JM. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023 May.159(5):545-553. Pubmedid: 36920356.
• Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 Mar.388(9):813-823. Pubmedid: 36856617.
• Amorrortu RP, Zhao Y, Stewart S, Ghia KM, Williams VL, Sondak VK, Tsai KY, Pinilla J, Chavez J, Rollison DE. History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience. J Cancer Res Clin Oncol. 2023 Jul.149(7):3607-3621. Pubmedid: 35962814.
• McClure E, Carr MJ, Patel A, Hussnain Naqvi SM, Kim Y, Harrington M, Cruse W, Gonzalez RJ, Sondak VK, Sarnaik AA, Messina JL, Zager JS. Atypical Fibroxanthoma: Outcomes from a Large Single Institution Series. Cancer Control. 2023 Jan.30. Pubmedid: 36764930. Pmcid: PMC9926370.
• McLouth LE, Zheng Y, Smith S, Hodi FS, Rao UN, Cohen GI, Amatruda TT, Dakhil SR, Curti BD, Nakhoul I, Chandana SR, Bane CL, Marinier DE, Lee SJ, Sondak VK, Kirkwood JM, Tarhini AA, Wagner LI. Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. Qual Life Res. 2023 Jan.32(1):183-196. Pubmedid: 36029412. Pmcid: PMC9839512.
• Tieniber AD, Shannon A, Carr MJ, Sun J, Landa K, Baecher KM, Lynch K, Bartels HG, Panchaud R, Lowe MC, Slingluff CL, Jameson MJ, Tsai KY, Faries MB, Beasley GM, Sondak VK, Karakousis GC, Zager JS, Miura JT. Patterns of recurrence and prognosis in pathologic stage I and II Merkel cell carcinoma: A multicenter, retrospective cohort analysis. J Am Acad Dermatol. 2023 Jan.88(1):251-253. Pubmedid: 35588924. Pmcid: PMC9667736.
• Shannon AB, Sharon CE, Straker RJ, Carr MJ, Sinnamon AJ, Bogatch K, Thaler A, Kelly N, Vetto JT, Fowler G, DePalo D, Sondak VK, Miura JT, Faries MB, Bartlett EK, Zager JS, Karakousis GC. Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort study. J Am Acad Dermatol. 2023 Jan.88(1):52-59. Pubmedid: 36184008.
• Unger JM, Darke A, Othus M, Truong TG, Khushalani N, Kendra K, Lewis KD, Faller B, Funchain P, Buchbinder EI, Tarhini AA, Kirkwood JM, Sharon E, Sondak V, Guild SR, Grossmann K, Ribas A, Patel SP. Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial. JAMA Oncol. 2023 Feb.9(2):251-260. Pubmedid: 36416836. Pmcid: PMC9685550.
• Moncrieff MD, Sondak VK, Thompson JF, Zager JS. Reply to A. Mangla and E. Hindié. J Clin Oncol. 2023 Feb.41(6):1326-1327. Pubmedid: 36455171.
• Perez MC, Messina JL, Karapetyan L, Neves RI, Sondak VK. Acral melanoma: clinical advances and hope for the future. Clin Adv Hematol Oncol. 2023 Aug.21(8):400-409. Pubmedid: 37530614.
• Eljilany I, Noor A, Paravathaneni M, Yassine I, Lee SJ, Othus M, Moon J, Kirkwood JM, Sondak VK, Ribas A, Grossmann KF, Tarhini AA. Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and SWOG S1404 Phase III Trials and a Literature Review. Cancers (Basel). 2023 Apr.15(9). Pubmedid: 37174027. Pmcid: PMC10177189.
• Amorrortu RP, Zhao Y, Fenske NA, Cherpelis BS, Messina JL, Giuliano AR, Sondak VK, Schell MJ, Mckay-Chopin S, Gheit T, Waterboer T, Tommasino M, Rollison DE. Natural History of Incident and Persistent Cutaneous Human Papillomavirus and Human Polyomavirus Infections. J Infect Dis. 2022 Sep.226(7):1162-1174. Pubmedid: 35022780. Pmcid: PMC9518839.
• Moncrieff MD, Lo SN, Scolyer RA, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyova R, Mason J, Wilson ED, Nolan G, Pritchard Jones R, Sondak VK, Thompson JF, Zager JS. Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. Ann Surg Oncol. 2022 Sep.29(9):5937-5945. Pubmedid: 35562521. Pmcid: PMC9356930.
• Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022 Sep.400(10357):1008-1019. Pubmedid: 36108657. Pmcid: PMC9533323.
• Shannon AB, Straker RJ, Carr MJ, Sun J, Landa K, Baecher K, Lynch K, Bartels HG, Panchaud R, Keele LJ, Lowe MC, Slingluff CL, Jameson MJ, Tsai KY, Faries MB, Beasley GM, Sondak VK, Karakousis GC, Zager JS, Miura JT. ASO Visual Abstract: An Internally Validated Prognostic Risk Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma. Ann Surg Oncol. 2022 Oct.29(11):7045-7046. Pubmedid: 35896923.
• Shannon AB, Straker RJ, Carr MJ, Sun J, Landa K, Baecher K, Lynch K, Bartels HG, Panchaud R, Keele LJ, Lowe MC, Slingluff CL, Jameson MJ, Tsai KY, Faries MB, Beasley GM, Sondak VK, Karakousis GC, Zager JS, Miura JT. An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma. Ann Surg Oncol. 2022 Oct.29(11):7033-7044. Pubmedid: 35867209.
• Sondak VK, Neves RI, Wuthrick EJ, Messina JL, Khushalani NI. Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma. Cancer. 2022 Nov.128(21):3764-3771. Pubmedid: 36066835.
• Moncrieff MD, Lo SN, Scolyer RA, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyova R, Mason J, Wilson ED, Nolan G, Jones RP, Sondak VK, Thompson JF, Zager JS. ASO Visual Abstract: Evaluation of Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International Multicenter Study. Ann Surg Oncol. 2022 May. Pubmedid: 35612683.
• Noyes D, Bag A, Oseni S, Semidey-Hurtado J, Cen L, Sarnaik AA, Sondak VK, Adeegbe D. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells. J Immunother Cancer. 2022 May.10(5). Pubmedid: 35618289. Pmcid: PMC9125763.
• Li J, Smalley I, Chen Z, Wu JY, Phadke MS, Teer JK, Nguyen T, Karreth FA, Koomen JM, Sarnaik AA, Zager JS, Khushalani NI, Tarhini AA, Sondak VK, Rodriguez PC, Messina JL, Chen YA, Smalley KSM. Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. Clin Cancer Res. 2022 May.28(10):2131-2146. Pubmedid: 35247927. Pmcid: PMC9106889.
• Grossmann KF, Othus M, Patel SP, Tarhini AA, Sondak VK, Knopp MV, Petrella TM, Truong TG, Khushalani NI, Cohen JV, Buchbinder EI, Kendra K, Funchain P, Lewis KD, Conry RM, Chmielowski B, Kudchadkar RR, Johnson DB, Li H, Moon J, Eroglu Z, Gastman B, Kovacsovics-Bankowski M, Gunturu KS, Ebbinghaus SW, Ahsan S, Ibrahim N, Sharon E, Korde LA, Kirkwood JM, Ribas A. Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma. Cancer Discov. 2022 Mar.12(3):644-653. Pubmedid: 34764195. Pmcid: PMC8904282.
• van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Jun.29(6):3694-3708. Pubmedid: 35089452.
• Saad M, Lee SJ, Tan AC, El Naqa IM, Hodi FS, Butterfield LH, LaFramboise WA, Storkus W, Karunamurthy AD, Conejo-Garcia J, Hwu P, Streicher H, Sondak VK, Kirkwood JM, Tarhini AA. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 Jun.20(1):253. Pubmedid: 35659704. Pmcid: PMC9164320.
• Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, Gastman BR, Kendra KL, Kluger H, Lipson EJ, Madden K, Miller DM, Nghiem P, Pavlick AC, Puzanov I, Rabinowits G, Ruiz ES, Sondak VK, Tavss EA, Tetzlaff MT, Brownell I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. J Immunother Cancer. 2022 Jul.10(7). Pubmedid: 35902131. Pmcid: PMC9341183.
• Holmberg CJ, Ny L, Hieken TJ, Block MS, Carr MJ, Sondak VK, Örtenwall C, Katsarelias D, Dimitriou F, Menzies AM, Saw RP, Rogiers A, Straker RJ, Karakousis G, Applewaite R, Pallan L, Han D, Vetto JT, Gyorki DE, Tie EN, Vitale MG, Ascierto PA, Dummer R, Cohen J, Hui JY, Schachter J, Asher N, Helgadottir H, Chai H, Kroon H, Coventry B, Rothermel LD, Sun J, Carlino MS, Duncan Z, Broman K, Weber J, Lee AY, Berman RS, Teras J, Ollila DW, Long GV, Zager JS, van Akkooi A, Olofsson Bagge R. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study. Eur J Cancer. 2022 Jul.169:210-222. Pubmedid: 35644725.
• Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022 Jan.10(1). Pubmedid: 35074904. Pmcid: PMC8788316.
• Broman KK, Hughes TM, Bredbeck BC, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, O'shea K, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Hotz M, Farma JM, Deneve JL, Fleming MD, Perez M, Baecher K, Lowe M, Bagge RO, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley GM, Hui JYC, Been L, Kruijff S, Sinco B, Sarnaik AA, Sondak VK, Zager JS, Dossett LA. International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node Positive Melanoma at Major Referral Centers. Ann Surg. 2022 Jan. Pubmedid: 35129464.
• Subramanian S, Han G, Olson N, Leong SP, Kashani-Sabet M, White RL, Zager JS, Sondak VK, Messina JL, Pockaj B, Kosiorek HE, Vetto J, Fowler G, Schneebaum S, Han D. Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence-free survival. J Surg Oncol. 2022 Feb.125(2):229-238. Pubmedid: 34535899.
• Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón Colón M, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mule JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA. Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Clin Cancer Res. 2022 Dec.28(24):5317-5329. Pubmedid: 36215121. Pmcid: PMC10324027.
• Moncrieff MD, Lo SN, Scolyer RA, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyova R, Mason J, Wilson ED, Nolan G, Pritchard Jones R, Johansson I, Olofsson Bagge R, Wright LJ, Patel NG, Sondak VK, Thompson JF, Zager JS. Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease. J Clin Oncol. 2022 Dec.40(34):3940-3951. Pubmedid: 35849790.
• van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero SVMA, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Bagge RO, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Aug.29(8):5241-5242. Pubmedid: 35426590.
• Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet. 2022 Apr.399(10336):1718-1729. Pubmedid: 35367007.
• Morrison SL, Han G, Elenwa F, Vetto JT, Fowler G, Leong SP, Kashani-Sabet M, Pockaj BA, Kosiorek HE, Zager JS, Sondak VK, Messina JL, Mozzillo N, Schneebaum S, Han D. Is the presence of tumor-infiltrating lymphocytes predictive of outcomes in patients with melanoma?. Cancer. 2022 Apr.128(7):1418-1428. Pubmedid: 35103302.
• Rollison DE, Amorrortu RP, Zhao Y, Messina JL, Schell MJ, Fenske NA, Cherpelis BS, Giuliano AR, Sondak VK, Pawlita M, McKay-Chopin S, Gheit T, Waterboer T, Tommasino M. Cutaneous Human Papillomaviruses and the Risk of Keratinocyte Carcinomas. Cancer Res. 2021 Sep.81(17):4628-4638. Pubmedid: 34266893. Pmcid: PMC8416805.
• Amorrortu RP, Zhao Y, Messina JL, Schell MJ, Fenske NA, Cherpelis BS, Sondak VK, Giuliano AR, Pawlita M, McKay-Chopin S, Gheit T, Waterboer T, Tommasino M, Rollison DE. Association between Human Polyomaviruses and Keratinocyte Carcinomas: A Prospective Cohort Study. Cancer Epidemiol Biomarkers Prev. 2021 Sep.30(9):1761-1764. Pubmedid: 34187857. Pmcid: PMC8419098.
• Sondak VK, Messina JL. What's new in pediatric melanoma and Spitz tumors? Pretty much everything. Cancer. 2021 Oct.127(20):3720-3723. Pubmedid: 34228362.
• Broman KK, Bettampadi D, Pérez-Morales J, Sun J, Kirichenko D, Carr MJ, Eroglu Z, Tarhini AA, Khushalani N, Schabath MB, Sarnaik A, Sondak VK, Zager JS. Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. Ann Surg Oncol. 2021 Nov.28(12):6978-6985. Pubmedid: 34363118. Pmcid: PMC8828269.
• Subramanian S, Han G, Olson N, Leong SP, Kashani-Sabet M, White RL, Zager JS, Sondak VK, Messina JL, Pockaj B, Kosiorek HE, Vetto J, Fowler G, Schneebaum S, Han D. Regression is significantly associated with outcomes for patients with melanoma. Surgery. 2021 Nov.170(5):1487-1494. Pubmedid: 34120749.
• Straker RJ, Carr MJ, Sinnamon AJ, Shannon AB, Sun J, Landa K, Baecher KM, Wood C, Lynch K, Bartels HG, Panchaud R, Lowe MC, Slingluff CL, Jameson MJ, Tsai K, Faries MB, Beasley GM, Sondak V, Karakousis GC, Zager JS, Miura JT. Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. Ann Surg Oncol. 2021 Nov.28(12):6995-7003. Pubmedid: 33890195.
• Tarhini AA, Kang N, Lee SJ, Hodi FS, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 May.9(5). Pubmedid: 33963015. Pmcid: PMC8108687.
• Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gerhsenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 May.27(10):2678-2697. Pubmedid: 33414132. Pmcid: PMC8127340.
• Smalley I, Chen Z, Phadke MS, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clin Cancer Res. 2021 Jul.27(14):4109-4125. Pubmedid: 34035069. Pmcid: PMC8282775.
• Broman KK, Hughes T, Dossett L, Sun J, Kirichenko D, Carr MJ, Sharma A, Bartlett EK, Nijhuis AAG, Thompson JF, Hieken TJ, Kottschade L, Downs J, Gyorki DE, Stahlie E, van Akkooi A, Ollila DW, Frank J, Song Y, Karakousis G, Moncrieff M, Nobes J, Vetto J, Han D, Farma JM, Deneve JL, Fleming MD, Perez MC, Lowe MC, Olofsson Bagge R, Mattsson J, Lee AY, Berman RS, Chai H, Kroon HM, Teras J, Teras RM, Farrow NE, Beasley G, Hui JYC, Been L, Kruijff S, Kim Y, Naqvi SMH, Sarnaik AA, Sondak VK, Zager JS. Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT-2). Cancer. 2021 Jul.127(13):2251-2261. Pubmedid: 33826754. Pmcid: PMC8764513.
• Straker RJ, Song Y, Sun J, Shannon AB, Cohen LS, Muradova E, Daou H, Krause K, Li S, Frederick DT, Rhodin KE, Brizel DM, Boland GM, Beasley GM, Wuthrick EJ, Sondak VK, Zager JS, Lin A, Lukens JN, Karakousis GC. Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul.28(7):3512-3521. Pubmedid: 33230747.
• Zhao Y, Amorrortu RP, Fenske NA, Cherpelis B, Messina JL, Sondak VK, Giuliano AR, Schell MJ, Waterboer T, Pawlita M, McKay-Chopin S, Gheit T, Tommasino M, Rollison DE. Cutaneous viral infections associated with ultraviolet radiation exposure. Int J Cancer. 2021 Jan.148(2):448-458. Pubmedid: 32818302. Pmcid: PMC7754468.
• Han D, Han G, Duque MT, Morrison S, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Sondak VK, Zager JS. Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas. Ann Surg Oncol. 2021 Feb.28(2):1007-1016. Pubmedid: 32524460.
• Broman KK, Bettampadi D, Pérez-Morales J, Sun J, Kirichenko D, Carr MJ, Eroglu Z, Tarhini AA, Khushalani N, Schabath MB, Sarnaik A, Sondak VK, Zager JS. ASO Visual Abstract: Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. Ann Surg Oncol. 2021 Dec.28(Suppl 3):678-679. Pubmedid: 34471988.
• Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ. Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma. J Clin Oncol. 2021 Aug.39(24):2647-2655. Pubmedid: 33945288. Pmcid: PMC8376314.
• Ascierto PA, Atkins MB, Eggermont AM, Gershenwald JE, Grob JJ, Hamid O, Sondak VK, Sosman JA, Tawbi HA, Weber JS, Caracò C, Osman I, Puzanov I. The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020. J Transl Med. 2021 Apr.19(1):142. Pubmedid: 33827575. Pmcid: PMC8028182.
• Karakousis G, Sondak VK, Zager JS. Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas. J Clin Oncol. 2020 Sep.38(27):3234-3235. Pubmedid: 32701416.
• Wang X, Yu X, Krauthammer M, Hugo W, Duan C, Kanetsky PA, Teer JK, Thompson ZJ, Kalos D, Tsai KY, Smalley KSM, Sondak VK, Chen YA, Conejo-Garcia JR. The Association of MUC16 Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. Cancer Epidemiol Biomarkers Prev. 2020 Sep.29(9):1792-1799. Pubmedid: 32611582. Pmcid: PMC7483810.
• Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 Sep.156(9):1004-1011. Pubmedid: 32725204. Pmcid: PMC8275355.
• Han D, Han G, Morrison S, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Sondak VK, Zager JS. Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?. Surgery. 2020 Sep.168(3):518-526. Pubmedid: 32669204.
• Seth R, Messersmith H, Kaur V, Kirkwood JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J, Alluri KC, Agarwala S, Ascierto PA, Atkins MB, Davis N, Ernstoff MS, Faries MB, Gold JS, Guild S, Gyorki DE, Khushalani NI, Meyers MO, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Tsai KK, van Akkooi A, Funchain P. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 Nov.38(33):3947-3970. Pubmedid: 32228358.
• Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, Arance A, Blank CU, Sileni VC, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Bagge RO, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Keilholz U. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020 Nov.31(11):1449-1461. Pubmedid: 32763452.
• Sondak V. The use of molecular testing at a diagnosis of melanoma. Clin Adv Hematol Oncol. 2020 Nov.18(11):700-702. Pubmedid: 33406061.
• Sondak VK, Messina JL, Tarhini AA. Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma. J Am Coll Surg. 2020 Nov.231(5):554-556. Pubmedid: 33491653.
• Gastman B, Agarwal PK, Berger A, Boland G, Broderick S, Butterfield LH, Byrd D, Fecci PE, Ferris RL, Fong Y, Goff SL, Grabowski MM, Ito F, Lim M, Lotze MT, Mahdi H, Malafa M, Morris CD, Murthy P, Neves RI, Odunsi A, Pai SI, Prabhakaran S, Rosenberg SA, Saoud R, Sethuraman J, Skitzki J, Slingluff CL, Sondak VK, Sunwoo JB, Turcotte S, Yeung CC, Kaufman HL. Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. J Immunother Cancer. 2020 Nov.8(2). Pubmedid: 33199512. Pmcid: PMC7670953.
• Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, Arance A, Blank CU, Sileni VC, Donia M, Faries MB, Gaudy-Marqueste C, Gogas H, Grob JJ, Guckenberger M, Haanen J, Hayes AJ, Hoeller C, Lebbé C, Lugowska I, Mandalà M, Márquez-Rodas I, Nathan P, Neyns B, Bagge RO, Puig S, Rutkowski P, Schilling B, Sondak VK, Tawbi H, Testori A, Michielin O. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020 Nov.31(11):1435-1448. Pubmedid: 32763453.
• Uppal A, Stern S, Thompson JF, Foshag L, Mizzollo N, Nieweg OE, Hoekstra HJ, Roses DF, Sondak VK, Kashani-Sabet M, Coventry BJ, Cochran AJ, Fujita M, Sim-Shin M, Elashoff D, Elashoff RM, Faries MB. Regional Node Basin Recurrence in Melanoma Patients: More Common After Node Dissection for Macroscopic Rather than Clinically Occult Nodal Disease. Ann Surg Oncol. 2020 Jun.27(6):1970-1977. Pubmedid: 31863416.
• Farley CR, Perez MC, Soelling SJ, Delman KA, Harit A, Wuthrick EJ, Messina JL, Sondak VK, Zager JS, Lowe MC. Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?. Ann Surg Oncol. 2020 Jun.27(6):1978-1985. Pubmedid: 32103415.
• Prieto-Granada C, Castner N, Chen A, Li J, Yue B, Wong JY, Iyengar S, Sondak VK, Zager JS, Messina JL. Behavior of Cutaneous Adnexal Malignancies: a Single Institution Experience. Pathol Oncol Res. 2020 Jan.26(1):239-244. Pubmedid: 29948620. Pmcid: PMC6294697.
• Eroglu Z, Eatrides J, Naqvi SMH, Kim Y, Rich J, Babacan NA, Brohl AS, Markowitz J, Sarnaik A, Zager J, Khushalani NI, Sondak VK, Messina J. Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell Melanoma Res. 2020 Jan.33(1):86-95. Pubmedid: 31329344. Pmcid: PMC6928428.
• Amorrortu RP, Fenske NA, Cherpelis BS, Vijayan L, Zhao Y, Balliu J, Messina JL, Sondak VK, Giuliano AR, Gheit T, Tommasino M, Rollison DE. Viruses in Skin Cancer (VIRUSCAN): Study Design and Baseline Characteristics of a Prospective Clinic-Based Cohort Study. Cancer Epidemiol Biomarkers Prev. 2020 Jan.29(1):39-48. Pubmedid: 31427307. Pmcid: PMC6954275.
• Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 Feb.38(6):567-575. Pubmedid: 31880964. Pmcid: PMC7030886.
• Farley CR, Perez MC, Soelling SJ, Delman KA, Harit A, Wuthrick EJ, Messina JL, Sondak VK, Zager JS, Lowe MC. Correction to: Merkel Cell Carcinoma Outcomes: Does AJCC8 Underestimate Survival?. Ann Surg Oncol. 2020 Dec.27(Suppl 3):983. Pubmedid: 32699930.
• Brohl AS, Sondak VK. Neoadjuvant Checkpoint Inhibitor Therapy for Merkel Cell Carcinoma. J Clin Oncol. 2020 Aug.38(22):2471-2475. Pubmedid: 32530767.
• Sun J, Kirichenko DA, Chung JL, Carr MJ, Eroglu Z, Khushalani NI, Markowitz J, Messina JL, Sondak VK, Zager JS, Patel SY. Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. World J Surg. 2020 Apr.44(4):1283-1293. Pubmedid: 31811340.
• Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2019 Oct.25(19):5961-5971. Pubmedid: 31399473. Pmcid: PMC6774882.
• Smalley I, Kim E, Li J, Spence P, Wyatt CJ, Eroglu Z, Sondak VK, Messina JL, Babacan NA, Maria-Engler SS, De Armas L, Williams SL, Gatenby RA, Chen YA, Anderson ARA, Smalley KSM. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma. EBioMedicine. 2019 Oct.48:178-190. Pubmedid: 31594749. Pmcid: PMC6838387.
• Eroglu Z, Holmen SL, Chen Q, Khushalani NI, Amaravadi R, Thomas R, Ahmed KA, Tawbi H, Chandra S, Markowitz J, Smalley I, Liu JKC, Ann Chen Y, Najjar YG, Karreth FA, Abate-Daga D, Glitza IC, Sosman JA, Sondak VK, Bosenberg M, Herlyn M, Atkins MB, Kluger H, Margolin K, Forsyth PA, Davies MA, Smalley KSM. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2019 May.32(3):458-469. Pubmedid: 30712316. Pmcid: PMC7771318.
• Klemen ND, Han G, Leong SP, Kashani-Sabet M, Vetto J, White R, Schneebaum S, Pockaj B, Mozzillo N, Charney K, Hoekstra H, Sondak VK, Messina JL, Zager JS, Han D. Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. J Surg Oncol. 2019 Jun.119(8):1053-1059. Pubmedid: 30883771.
• Emmons MF, Faião-Flores F, Sharma R, Thapa R, Messina JL, Becker JC, Schadendorf D, Seto E, Sondak VK, Koomen JM, Chen YA, Lau EK, Wan L, Licht JD, Smalley KSM. HDAC8 Regulates a Stress Response Pathway in Melanoma to Mediate Escape from BRAF Inhibitor Therapy. Cancer Res. 2019 Jun.79(11):2947-2961. Pubmedid: 30987999. Pmcid: PMC6548652.
• Perez MC, Sun J, Farley C, Han D, Sun AH, Narayan D, Lowe M, Delman KA, Messina JL, Gonzalez RJ, Sondak VK, Khushalani NI, Zager JS. Management of intussusception in patients with melanoma. J Surg Oncol. 2019 Jun.119(7):897-902. Pubmedid: 30734297.
• Thomas DC, Han G, Leong SP, Kashani-Sabet M, Vetto J, Pockaj B, White RL, Faries MB, Schneebaum S, Mozzillo N, Charney KJ, Sondak VK, Messina JL, Zager JS, Han D. Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival. Ann Surg Oncol. 2019 Jul.26(7):2254-2262. Pubmedid: 31011906.
• Rothermel LD, Sarnaik AA, Khushalani NI, Sondak VK. Current Immunotherapy Practices in Melanoma. Surg Oncol Clin N Am. 2019 Jul.28(3):403-418. Pubmedid: 31079796.
• Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, Hong A, Kirkwood JM, Lo S, Margolin K, Messina J, Postow MA, Rizos H, Ross MI, Rozeman EA, Saw RPM, Sondak V, Sullivan RJ, Taube JM, Thompson JF, van de Wiel BA, Eggermont AM, Davies MA, Ascierto PA, Spillane AJ, van Akkooi ACJ, Wargo JA, Blank CU, Tawbi HA, Long GV. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 Jul.20(7):e378-e389. Pubmedid: 31267972.
• Karakousis GC, Gimotty PA, Leong SP, Pockaj BA, White RL, O'Donoghue C, Sinnamon AJ, Bartlett EK, Dueck AC, Gould Rothberg BE, Messina JL, Vetto JT, Sondak VK, Schneebaum S, Kashani-Sabet M, Han D, Faries MB, Zager JS. Microsatellitosis in Patients with Melanoma. Ann Surg Oncol. 2019 Jan.26(1):33-41. Pubmedid: 30421045.
• Jeter JM, Bowles TL, Curiel-Lewandrowski C, Swetter SM, Filipp FV, Abdel-Malek ZA, Geskin LJ, Brewer JD, Arbiser JL, Gershenwald JE, Chu EY, Kirkwood JM, Box NF, Funchain P, Fisher DE, Kendra KL, Marghoob AA, Chen SC, Ming ME, Albertini MR, Vetto JT, Margolin KA, Pagoto SL, Hay JL, Grossman D, Ellis DL, Kashani-Sabet M, Mangold AR, Markovic SN, Nelson KC, Powers JG, Robinson JK, Sahni D, Sekulic A, Sondak VK, Wei ML, Zager JS, Dellavalle RP, Thompson JA, Weinstock MA, Leachman SA, Cassidy PB. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 Jan.125(1):18-44. Pubmedid: 30281145. Pmcid: PMC6860362.
• Perez MC, Oliver DE, Weitman ES, Boulware D, Messina JL, Torres-Roca J, Cruse CW, Gonzalez RJ, Sarnaik AA, Sondak VK, Wuthrick EJ, Harrison LB, Zager JS. Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?. Ann Surg Oncol. 2019 Feb.26(2):379-385. Pubmedid: 30311164. Pmcid: PMC7771265.
• Sondak VK, Khushalani NI. Echoes of a failure: what lessons can we learn?. Lancet Oncol. 2019 Aug.20(8):1037-1039. Pubmedid: 31221617.
• Weitman ES, Perez MC, Lee D, Kim Y, Fulp W, Sondak VK, Sarnaik AA, Gonzalez RJ, Cruse CW, Messina JL, Zager JS. Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins. Melanoma Manag. 2019 Apr.6(2):MMT17. Pubmedid: 31406562. Pmcid: PMC6688556.
• Perez MC, de Pinho FR, Holstein A, Oliver DE, Naqvi SMH, Kim Y, Messina JL, Burke E, Gonzalez RJ, Sarnaik AA, Cruse CW, Wuthrick EJ, Harrison LB, Sondak VK, Zager JS. Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?. Ann Surg Oncol. 2018 Oct.25(11):3334-3340. Pubmedid: 30073600. Pmcid: PMC7771268.
• Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAF V600E-Mutant Melanoma. Clin Cancer Res. 2018 Nov.24(22):5516-5524. Pubmedid: 29674508. Pmcid: PMC6195480.
• Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 May.6(1):44. Pubmedid: 29848375. Pmcid: PMC5977556.
• Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT. Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma. Cancer. 2018 May.124(10):2254-2255. Pubmedid: 29543319.
• Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018 Mar.8:44. Pubmedid: 29552542. Pmcid: PMC5840208.
• Oliver DE, Sondak VK, Strom T, Zager JS, Naghavi AO, Sarnaik A, Messina JL, Caudell JJ, Trotti AM, Torres-Roca JF, Khushalani NI, Harrison LB. Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. Melanoma Manag. 2018 Jun.5(1):MMT02. Pubmedid: 30190928. Pmcid: PMC6122528.
• Burke EE, Sondak VK. Surgical management of melanoma. Semin Cutan Med Surg. 2018 Jun.37(2):101-108. Pubmedid: 30040086.
• Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mulé JJ, Smalley KS, Weber JS, Zager JS, Forsyth PA, Sondak VK, Gibney GT. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer. 2018 Jan.124(2):297-305. Pubmedid: 29023643. Pmcid: PMC7771556.
• Verduzco D, Kuenzi BM, Kinose F, Sondak VK, Eroglu Z, Rix U, Smalley KSM. Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. Mol Cancer Ther. 2018 Jan.17(1):73-83. Pubmedid: 29133622. Pmcid: PMC5752595.
• Porubsky C, Teer JK, Zhang Y, Deschaine M, Sondak V, Messina JL. Genomic analysis of a case of agminated Spitz nevi and congenital-pattern nevi arising in extensive nevus spilus. J Cutan Pathol. 2018 Feb.45(2):180-183. Pubmedid: 29210482. Pmcid: PMC5768454.
• Chang JM, Kosiorek HE, Dueck AC, Leong SPL, Vetto JT, White RL, Avisar E, Sondak VK, Messina JL, Zager JS, Garberoglio C, Kashani-Sabet M, Pockaj BA. Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg. 2018 Apr.215(4):699-706. Pubmedid: 29502857. Pmcid: PMC5978691.
• Sreeraman Kumar R, Thapa R, Kim Y, Khushalani NI, Sondak VK, Reed DR. Higher than reported adolescent and young adult clinical trial enrollment during the "Golden Age" of melanoma clinical trials. Cancer Med. 2018 Apr.7(4):991-996. Pubmedid: 29478277. Pmcid: PMC5911596.
• Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE. High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov.6(11):2576-2585. Pubmedid: 28994212. Pmcid: PMC5673911.
• Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA-Cancer J Clin. 2017 Nov.67(6):472-492. Pubmedid: 29028110. Pmcid: PMC5978683.
• Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. Melanoma Manag. 2017 Mar.4(1):13-37. Pubmedid: 28758010. Pmcid: PMC5480135.
• Agarwala SS, Lee SJ, Yip W, Rao UN, Tarhini AA, Cohen GI, Reintgen DS, Evans TL, Brell JM, Albertini MR, Atkins MB, Dakhil SR, Conry RM, Sosman JA, Flaherty LE, Sondak VK, Carson WE, Smylie MG, Pappo AS, Kefford RF, Kirkwood JM. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro. J Clin Oncol. 2017 Mar.35(8):885-892. Pubmedid: 28135150. Pmcid: PMC5455684.
• Glazer ES, Porubsky CF, Francis JD, Ibanez J, Castner N, Messina JL, Sarnaik AA, Harrington MA, Cruse CW, Sondak VK, Zager JS. Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions. Ann Plast Surg. 2017 Jun.78(6):663-667. Pubmedid: 27984218. Pmcid: PMC5425303.
• Strom T, Naghavi AO, Messina JL, Kim S, Torres-Roca JF, Russell J, Sondak VK, Padhya TA, Trotti AM, Caudell JJ, Harrison LB. Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck. Head Neck. 2017 Jan.39(1):48-55. Pubmedid: 27300153.
• Doepker MP, Yamamoto M, Applebaum MA, Patel NU, Jaime Montilla-Soler M, Sarnaik AA, Wayne Cruse C, Sondak VK, Zager JS. Comparison of Single-Photon Emission Computed Tomography-Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies. Ann Surg Oncol. 2017 Feb.24(2):355-361. Pubmedid: 27660259. Pmcid: PMC5955617.
• Chai C, Szabunio M, Cook C, Zager J, Messina J, Chau A, Sondak V. Pre-SN Ultrasound-FNAC for Lymph Node Metastases in Melanoma Patients: A Reply. Ann Surg Oncol. 2017 Dec.24(Suppl 3):663-664. Pubmedid: 29134381.
• Strom T, Torres-Roca JF, Parekh A, Naghavi AO, Caudell JJ, Oliver DE, Messina JL, Khushalani NI, Zager JS, Sarnaik A, Mulé JJ, Trotti AM, Eschrich SA, Sondak VK, Harrison LB. Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. J Natl Compr Canc Ne. 2017 Apr.15(4):473-482. Pubmedid: 28404758. Pmcid: PMC7771284.
• Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017 Apr.75:47-55. Pubmedid: 28214657.
• Sondak VK, Messina JL, Zager JS. Selecting Patients With Thin Melanoma for Sentinel Lymph Node Biopsy-This Time It's Personal. JAMA Dermatol. 2017 09.153(9):857-858. Pubmedid: 28724141.
• Forsyth PA, Smalley KSM, Sondak VK. BRAF-MEK inhibition in melanoma brain metastases: a new hope. Lancet Oncol. 2017 07.18(7):836-837. Pubmedid: 28677560.
• Sondak VK, Khushalani NI. Adjuvant and Neoadjuvant Therapy in High-Risk Stage III Cutaneous Melanoma. Int J Radiat Oncol Biol Phys. 2017 05.98(1):16-17. Pubmedid: 28586957.
• Sondak VK, Messina JL. Prediction is Difficult, Especially About the Future: Clinical Prognostic Tools in Melanoma. Ann Surg Oncol. 2016 Sep.23(9):2730-2732. Pubmedid: 27198510.
• Bhatia S, Storer BE, Iyer JG, Moshiri A, Parvathaneni U, Byrd D, Sober AJ, Sondak VK, Gershenwald JE, Nghiem P. Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. J Natl Cancer Inst. 2016 Sep.108(9). Pubmedid: 27245173. Pmcid: PMC6059142.
• Parekh A, Strom T, Naghavi AO, Caudell JJ, Zager JS, Messina JL, Torres-Roca JF, Sondak VK, Trotti A, Harrison LB. Does Regional Radiation Therapy Impact Outcome for High-Risk, Node-Positive Cutaneous Melanoma?. Int J Radiat Oncol Biol Phys. 2016 Oct.96(2S):S157. Pubmedid: 27675666.
• Strom T, Carr M, Zager JS, Naghavi A, Smith FO, Cruse CW, Messina JL, Russell J, Rao NG, Fulp W, Kim S, Torres-Roca JF, Padhya TA, Sondak VK, Trotti AM, Harrison LB, Caudell JJ. Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Ann Surg Oncol. 2016 Oct.23(11):3572-3578. Pubmedid: 27251134.
• Sarnaik AA, Zager JS, Sondak VK. Point: Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive Melanoma. Oncology (Williston Park). 2016 Oct.30(10):891-2-895. Pubmedid: 27753054.
• Hampras SS, Reed RA, Bezalel S, Cameron M, Cherpelis B, Fenske N, Sondak VK, Messina J, Tommasino M, Gheit T, Rollison DE. Cutaneous Human Papillomavirus Infection and Development of Subsequent Squamous Cell Carcinoma of the Skin. J Skin Cancer. 2016 Nov.2016:1368103. Pubmedid: 27891253. Pmcid: PMC5116506.
• Prabhakaran S, Fulp WJ, Gonzalez RJ, Sondak VK, Kudchadkar RR, Gibney GT, Weber JS, Zager JS. Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. Am Surg. 2016 Nov.82(11):1109-1116. Pubmedid: 28206940.
• Prabhakaran S, Fulp WJ, Gonzalez RJ, Sondak VK, Kudchadkar RR, Gibney GT, Weber JS, Zager JS. Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. Am Surg. 2016 Nov.82(11):1109-1116. Pubmedid: 28877811.
• Gershenwald JE, Halpern AC, Sondak VK. Melanoma Prevention-Avoiding Indoor Tanning and Minimizing Overexposure to the Sun. Jama. 2016 Nov.316(18):1913-1914. Pubmedid: 27824997.
• Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, Smalley KS. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. 2016 Mar.35(10):1225-1235. Pubmedid: 26073081. Pmcid: PMC4679729.
• Eroglu Z, Smalley KS, Sondak VK. Improving patient outcomes to targeted therapies in melanoma. Expert Rev Anticancer Ther. 2016 Jun.16(6):633-641. Pubmedid: 27137746.
• Doepker MP, Thompson ZJ, Fisher KJ, Yamamoto M, Nethers KW, Harb JN, Applebaum MA, Gonzalez RJ, Sarnaik AA, Messina JL, Sondak VK, Zager JS. Is a Wider Margin (2 cm vs. 1 cm) for a 1.01-2.0 mm Melanoma Necessary?. Ann Surg Oncol. 2016 Jul.23(7):2336-2342. Pubmedid: 26957503. Pmcid: PMC4904729.
• Doepker MP, Thompson ZJ, Harb JN, Messina JL, Puleo CA, Egan KM, Sarnaik AA, Gonzalez RJ, Sondak VK, Zager JS. Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy. J Surg Oncol. 2016 Jan.113(1):98-102. Pubmedid: 26661407. Pmcid: PMC4904728.
• Sreeraman Kumar R, Messina JL, Reed D, Navid F, Sondak VK. Pediatric Melanoma and Atypical Melanocytic Neoplasms. Cancer Treat Res. 2016 Jan.167:331-369. Pubmedid: 26601871.
• Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy. Melanoma Res. 2016 Feb.26(1):83-87. Pubmedid: 26731560.
• Sharma R, Fedorenko I, Spence PT, Sondak VK, Smalley KS, Koomen JM. Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition. J Proteome Res. 2016 Dec.15(12):4476-4489. Pubmedid: 27934295. Pmcid: PMC5642956.
• Ozgun A, Sondak VK, Markowitz J. Resistance patterns to anti-PD-1 therapy in metastatic melanoma. Chin Clin Oncol. 2016 Dec.5(6):75. Pubmedid: 27701871. Pmcid: PMC6776879.
• Dossett LA, Castner NB, Pow-Sang JM, Abbott AM, Sondak VK, Sarnaik AA, Zager JS. Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy. J Am Coll Surg. 2016 Apr.222(4):702-709. Pubmedid: 26875071. Pmcid: PMC4871144.
• Sung H, Kanchi KL, Wang X, Hill KS, Messina JL, Lee JH, Kim Y, Dees ND, Ding L, Teer JK, Yang S, Sarnaik AA, Sondak VK, Mulé JJ, Wilson RK, Weber JS, Kim M. Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget. 2016 Apr.7(17):23885-23896. Pubmedid: 26993606. Pmcid: PMC5029671.
• Smalley KS, Eroglu Z, Sondak VK. Combination Therapies for Melanoma: A New Standard of Care?. Am J Clin Dermatol. 2016 Apr.17(2):99-105. Pubmedid: 26860106. Pmcid: PMC4805442.
• Khushalani NI, Sondak VK. Are we there yet? Prolonged MAPK inhibition in BRAF(V600)-mutant melanoma. Lancet Oncol. 2016 09.17(9):1178-1179. Pubmedid: 27480104.
• Sondak VK, McIver B, Kanetsky PA. Vitamin D and Melanoma: What Do We Tell Our Patients?. J Clin Oncol. 2016 05.34(15):1713-1714. Pubmedid: 27044934.
• Sondak VK, Reed D, Messina JL. A Comprehensive Approach to Pediatric Atypical Melanocytic Neoplasms with Comment on the Role of Sentinel Lymph Node Biopsy. Crit Rev Oncog. 2016.21(1-2):25-36. Pubmedid: 27481000.
• Smith FO, Yue B, Marzban SS, Walls BL, Carr M, Jackson RS, Puleo CA, Padhya T, Cruse CW, Gonzalez RJ, Sarnaik AA, Schell MJ, DeConti RC, Messina JL, Sondak VK, Zager JS. Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma. Cancer. 2015 Sep.121(18):3252-3260. Pubmedid: 26038193. Pmcid: PMC4904725.
• DeVito N, Henderson E, Han G, Reed D, Bui MM, Lavey R, Robinson L, Zager JS, Gonzalez RJ, Sondak VK, Letson GD, Conley A. Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience. PLoS One. 2015 Oct.10(10):e0140362. Pubmedid: 26469269. Pmcid: PMC4607370.
• Phadke M, Gibney GT, Rich CJ, Fedorenko IV, Chen Ann Y, Kudchadkar RR, Sondak VK, Weber J, Messina JL, Smalley KS. XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation. J Invest Dermatol. 2015 Oct.135(10):2542-2544. Pubmedid: 26039542. Pmcid: PMC4567904.
• Hampras SS, Michel A, Schmitt M, Waterboer T, Kranz L, Gheit T, Fisher K, Sondak VK, Messina J, Fenske N, Cherpelis B, Tommasino M, Pawlita M, Rollison DE. Merkel cell polyomavirus (MCV) T-antigen seroreactivity, MCV DNA in eyebrow hairs, and squamous cell carcinoma. Infect Agent Cancer. 2015 Oct.10:35. Pubmedid: 26483848. Pmcid: PMC4610041.
• Yamamoto M, Fisher KJ, Wong JY, Koscso JM, Konstantinovic MA, Govsyeyev N, Messina JL, Sarnaik AA, Cruse CW, Gonzalez RJ, Sondak VK, Zager JS. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. Cancer. 2015 May.121(10):1628-1636. Pubmedid: 25677366. Pmcid: PMC4515965.
• Sondak VK, McArthur GA. Adjuvant immunotherapy for cancer: the next step. Lancet Oncol. 2015 May.16(5):478-480. Pubmedid: 25840692.
• Paraiso KH, Thakur MD, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, Sloot S, Gibney GT, Stuart D, Tawbi H, Smalley KS. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar.5(3):264-273. Pubmedid: 25542447. Pmcid: PMC4355213.
• Han D, Han G, Zhao X, Rao NG, Messina JL, Marzban SS, Sarnaik AA, Cruse CW, Sondak VK, Zager JS. Clinicopathologic predictors of survival in patients with desmoplastic melanoma. PLoS One. 2015 Mar.10(3):e0119716. Pubmedid: 25811671. Pmcid: PMC4374691.
• Fedorenko IV, Gibney GT, Sondak VK, Smalley KS. Beyond BRAF: where next for melanoma therapy?. Brit J Cancer. 2015 Jan.112(2):217-226. Pubmedid: 25180764. Pmcid: PMC4453440.
• Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, Robert C, Schadendorf D, Sondak VK, Wolchok JD, Hudson AM. Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncol. 2015 Jan.16(1):15-17. Pubmedid: 25638540.
• Locke FL, Rollison DE, Sondak VK. Merkel cell carcinoma and immunosuppression: what we still need to know. J Natl Cancer Inst. 2015 Feb.107(2). Pubmedid: 25575646.
• Sondak VK, Glass LF, Geller AC. Risk-stratified screening for detection of melanoma. Jama. 2015 Feb.313(6):616-617. Pubmedid: 25668265.
• Lee SM, Moon J, Redman BG, Chidiac T, Flaherty LE, Zha Y, Othus M, Ribas A, Sondak VK, Gajewski TF, Margolin KA. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015 Feb.121(3):432-440. Pubmedid: 25250858. Pmcid: PMC4304973.
• Hampras SS, Rollison DE, Tommasino M, Gheit T, Schabath MB, Messina JL, Fenske NA, Cherpelis BS, Sondak VK, Iannacone MR, Schmitt M, Pawlita M. Genetic variations in the epidermodysplasia verruciformis (EVER/TMC) genes, cutaneous human papillomavirus infection and squamous cell carcinoma of the skin. Br J Dermatol. 2015 Dec.173(6):1532-1535. Pubmedid: 26126409. Pmcid: PMC4695259.
• Smalley KS, Sondak VK. Inhibition of BRAF and MEK in BRAF-mutant melanoma. Lancet. 2015 Aug.386(9992):410-412. Pubmedid: 26037942.
• Sondak VK, Gibney GT. Indications and options for systemic therapy in melanoma. Surg Clin N Am. 2014 Oct.94(5):1049-58, viii. Pubmedid: 25245967.
• Sondak VK, Messina JL. Unusual presentations of melanoma: melanoma of unknown primary site, melanoma arising in childhood, and melanoma arising in the eye and on mucosal surfaces. Surg Clin N Am. 2014 Oct.94(5):1059-73, ix. Pubmedid: 25245968.
• Carson WE, Unger JM, Sosman JA, Flaherty LE, Tuthill R, Porter MJ, Thompson JA, Kempf RA, Othus M, Ribas A, Sondak VK. Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res. 2014 Oct.2(10):981-987. Pubmedid: 24994597. Pmcid: PMC4185232.
• Ding L, Kim M, Kanchi KL, Dees ND, Lu C, Griffith M, Fenstermacher D, Sung H, Miller CA, Goetz B, Wendl MC, Griffith O, Cornelius LA, Linette GP, McMichael JF, Sondak VK, Fields RC, Ley TJ, Mulé JJ, Wilson RK, Weber JS. Clonal architectures and driver mutations in metastatic melanomas. PLoS One. 2014 Nov.9(11):e111153. Pubmedid: 25393105. Pmcid: PMC4230926.
• Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Moon J, Ribas A, Kirkwood JM, Sondak VK. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch. J Clin Oncol. 2014 Nov.32(33):3771-3778. Pubmedid: 25332243. Pmcid: PMC4226807.
• Iannacone MR, Gheit T, Pfister H, Giuliano AR, Messina JL, Fenske NA, Cherpelis BS, Sondak VK, Roetzheim RG, Silling S, Pawlita M, Tommasino M, Rollison DE. Case-control study of genus-beta human papillomaviruses in plucked eyebrow hairs and cutaneous squamous cell carcinoma. Int J Cancer. 2014 May.134(9):2231-2244. Pubmedid: 24136717. Pmcid: PMC4545525.
• Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amavaradi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res. 2014 May.27(3):465-478. Pubmedid: 24490764. Pmcid: PMC3988257.
• Strom T, Caudell JJ, Han D, Zager JS, Yu D, Cruse CW, Marzban SS, Messina JL, Trotti AM, Sondak VK, Rao NG. Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer. 2014 May.120(9):1369-1378. Pubmedid: 24142775. Pmcid: PMC4515972.
• Chapman PB, Hauschild A, Sondak VK. Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice. Am Soc Clin Oncol Educ Book. 2014 May.e412-e421. Pubmedid: 24857132.
• Sondak VK, Zager JS. Melanoma: MSLT-1--putting sentinel lymph node biopsy into context. Nat Rev Clin Oncol. 2014 May.11(5):246-248. Pubmedid: 24732944.
• Sondak VK, Gibney GT. Setting the bar for adjuvant treatment of melanoma. Lancet Oncol. 2014 May.15(6):547-548. Pubmedid: 24745697.
• Zager JS, Messina JL, Glass LF, Sondak VK. Unanswered questions in the management of stage I-III Merkel cell carcinoma. J Natl Compr Canc Ne. 2014 Mar.12(3):425-431. Pubmedid: 24616546.
• Sondak VK, Gibney GT. Surgical management of melanoma. Hematol Oncol Clin North Am. 2014 Jun.28(3):455-470. Pubmedid: 24880941.
• Rebecca VW, Wood ER, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS. Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics. 2014 Jul.13(7):1844-1854. Pubmedid: 24760959. Pmcid: PMC4083119.
• Kudchadkar R, Gibney G, Sondak VK. Integrating molecular biomarkers into current clinical management in melanoma. Methods Mol Biol. 2014 Jan.1102:27-42. Pubmedid: 24258972.
• Smyth T, Paraiso KH, Hearn K, Rodriguez-Lopez AM, Munck JM, Haarberg HE, Sondak VK, Thompson NT, Azab M, Lyons JF, Smalley KS, Wallis NG. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther. 2014 Dec.13(12):2793-2804. Pubmedid: 25349308. Pmcid: PMC4263034.
• Gibney GT, Sondak VK, Smalley KS. Where to start with systemic melanoma therapy?. Melanoma Manag. 2014 Aug.1(1):15-18. Pubmedid: 30190805. Pmcid: PMC6094590.
• Sondak V. A melanoma odyssey - a conversation with Vernon Sondak about a career in melanoma treatment and research. Melanoma Manag. 2014 Aug.1(1):25-30. Pubmedid: 30190807. Pmcid: PMC6094621.
• Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, Mihm MC, Morton DL, Atkins MB, Flaherty KT, Sondak VK. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr.21(4):1075-1081. Pubmedid: 24531700. Pmcid: PMC4121329.
• Iyer JG, Storer BE, Paulson KG, Lemos B, Phillips JL, Bichakjian CK, Zeitouni N, Gershenwald JE, Sondak V, Otley CC, Yu SS, Johnson TM, Liegeois NJ, Byrd D, Sober A, Nghiem P. Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell carcinoma. J Am Acad Dermatol. 2014 Apr.70(4):637-643. Pubmedid: 24521828. Pmcid: PMC3959572.
• Etzkorn JR, Parikh RP, Marzban SS, Law K, Davis AH, Rawal B, Schell MJ, Sondak VK, Messina JL, Rendina LE, Zager JS, Lien MH. Identifying risk factors using a skin cancer screening program. Cancer Control. 2013 Oct.20(4):248-254. Pubmedid: 24077401. Pmcid: PMC4516026.
• Kenchappa RS, Tran N, Rao NG, Smalley KS, Gibney GT, Sondak VK, Forsyth PA. Novel treatments for melanoma brain metastases. Cancer Control. 2013 Oct.20(4):298-306. Pubmedid: 24077406.
• Deneve JL, Messina JL, Bui MM, Marzban SS, Letson GD, Cheong D, Gonzalez RJ, Sondak VK, Zager JS. Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection. Cancer Control. 2013 Oct.20(4):307-312. Pubmedid: 24077407. Pmcid: PMC4504421.
• Perez MC, Padhya TA, Messina JL, Jackson RS, Gonzalez RJ, Bui MM, Letson GD, Cruse CW, Lavey RS, Cheong D, Forster MR, Fulp WJ, Sondak VK, Zager JS. Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol. 2013 Oct.20(11):3391-3397. Pubmedid: 23835652. Pmcid: PMC4509495.
• Kaufman HL, Kirkwood JM, Hodi FS, Agarwala S, Amatruda T, Bines SD, Clark JI, Curti B, Ernstoff MS, Gajewski T, Gonzalez R, Hyde LJ, Lawson D, Lotze M, Lutzky J, Margolin K, McDermott DF, Morton D, Pavlick A, Richards JM, Sharfman W, Sondak VK, Sosman J, Steel S, Tarhini A, Thompson JA, Titze J, Urba W, White R, Atkins MB. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 Oct.10(10):588-598. Pubmedid: 23982524.
• Weber JL, Smalley KS, Sondak VK, Gibney GT. Conjunctival melanomas harbor BRAF and NRAS mutations--Letter. Clin Cancer Res. 2013 Nov.19(22):6329-6330. Pubmedid: 24166902. Pmcid: PMC4666498.
• Averbook BJ, Lee SJ, Delman KA, Gow KW, Zager JS, Sondak VK, Messina J, Sabel M, Pittelkow M, Ecker PM, Markovic SN, Swetter SM, Leachman SA, Testori A, Curiel-Lewandrowski C, Go RS, Jukic DM, Kirkwood JM. Pediatric melanoma: analysis of an international registry. Cancer. 2013 Nov.119(22):4012-4019. Pubmedid: 24022819. Pmcid: PMC4096292.
• Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov.20(12):3961-3968. Pubmedid: 23838920. Pmcid: PMC4121330.
• Deneve JL, Turaga KK, Marzban SS, Puleo CA, Sarnaik AA, Gonzalez RJ, Sondak VK, Zager JS. Single-institution outcome experience using AlloDerm® as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects. Am Surg. 2013 May.79(5):476-482. Pubmedid: 23635582. Pmcid: PMC4505800.
• Park JY, Amankwah EK, Anic GM, Lin HY, Walls B, Park H, Krebs K, Madden M, Maddox K, Marzban S, Fang S, Chen W, Lee JE, Wei Q, Amos CI, Messina JL, Sondak VK, Sellers TA, Egan KM. Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. Cancer Epidemiol Biomarkers Prev. 2013 May.22(5):827-834. Pubmedid: 23462921. Pmcid: PMC3708315.
• Bhatia S, Moon J, Margolin KA, Weber JS, Lao CD, Othus M, Aparicio AM, Ribas A, Sondak VK. Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512. PLoS One. 2013 May.7(11):e48787. Pubmedid: 23226204. Pmcid: PMC3511501.
• Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?. Sci Rep. 2013 Mar.2:765. Pubmedid: 23097687. Pmcid: PMC3479449.
• Iannacone MR, Gheit T, Waterboer T, Giuliano AR, Messina JL, Fenske NA, Cherpelis BS, Sondak VK, Roetzheim RG, Ferrer-Gil S, Michael KM, McKay-Chopin S, Pawlita M, Tommasino M, Rollison DE. Case-control study of cutaneous human papillomavirus infection in Basal cell carcinoma of the skin. J Invest Dermatol. 2013 Jun.133(6):1512-1520. Pubmedid: 23303448. Pmcid: PMC4545594.
• Haarberg HE, Paraiso KH, Wood E, Rebecca VW, Sondak VK, Koomen JM, Smalley KS. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther. 2013 Jun.12(6):901-912. Pubmedid: 23538902. Pmcid: PMC3683468.
• Reed D, Kudchadkar R, Zager JS, Sondak VK, Messina JL. Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults. J Natl Compr Canc Ne. 2013 Jun.11(6):679-686. Pubmedid: 23744867. Pmcid: PMC4530628.
• Sondak VK, Wong SL, Gershenwald JE, Thompson JF. Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma. Am Soc Clin Oncol Educ Book. 2013 Jun. Pubmedid: 23714536.
• Sondak VK, Kudchadkar R. Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?. Oncologist. 2013 Jun.17(10):1223-1224. Pubmedid: 23002125. Pmcid: PMC3481887.
• Iarrobino A, Messina JL, Kudchadkar R, Sondak VK. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2013 Jul.69(1):e33-e34. Pubmedid: 23768306.
• Han D, Zager JS, Yu D, Zhao X, Walls B, Marzban SS, Rao NG, Sondak VK, Messina JL. Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?. Ann Surg Oncol. 2013 Jul.20(7):2345-2351. Pubmedid: 23389470. Pmcid: PMC4503324.
• Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS. Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol. 2013 Jul.10(7):390-399. Pubmedid: 23712190. Pmcid: PMC3983565.
• Gibney GT, Sondak VK. Has targeted therapy for melanoma made chemotherapy obsolete?. Lancet Oncol. 2013 Jul.14(8):676-677. Pubmedid: 23816289.
• Smalley KS, Sondak VK. Targeted therapy for melanoma: is double hitting a home run?. Nat Rev Clin Oncol. 2013 Jan.10(1):5-6. Pubmedid: 23207793.
• Sondak VK, King DW, Zager JS, Schneebaum S, Kim J, Leong SP, Faries MB, Averbook BJ, Martinez SR, Puleo CA, Messina JL, Christman L, Wallace AM. Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013 Feb.20(2):680-688. Pubmedid: 23054107. Pmcid: PMC3560941.
• Han D, Zager JS, Shyr Y, Chen H, Berry LD, Iyengar S, Djulbegovic M, Weber JL, Marzban SS, Sondak VK, Messina JL, Vetto JT, White RL, Pockaj B, Mozzillo N, Charney KJ, Avisar E, Krouse R, Kashani-Sabet M, Leong SP. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013 Dec.31(35):4387-4393. Pubmedid: 24190111.
• Anic GM, Sondak VK, Messina JL, Fenske NA, Zager JS, Cherpelis BS, Lee JH, Fulp WJ, Epling-Burnette PK, Park JY, Rollison DE. Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiol. 2013 Aug.37(4):434-439. Pubmedid: 23523330. Pmcid: PMC3679277.
• Tafreshi NK, Silva A, Estrella VC, McCardle TW, Chen T, Jeune-Smith Y, Lloyd MC, Enkemann SA, Smalley KS, Sondak VK, Vagner J, Morse DL. In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma. Mol Pharm. 2013 Aug.10(8):3175-3185. Pubmedid: 23763620. Pmcid: PMC3785103.
• Farma JM, Zager JS, Barnica-Elvir V, Puleo CA, Marzban SS, Rollison DE, Messina JL, Sondak VK. A collision of diseases: chronic lymphocytic leukemia discovered during lymph node biopsy for melanoma. Ann Surg Oncol. 2013 Apr.20(4):1360-1364. Pubmedid: 23179994. Pmcid: PMC4606461.
• Iannacone MR, Wang W, Stockwell HG, O'Rourke K, Giuliano AR, Sondak VK, Messina JL, Roetzheim RG, Cherpelis BS, Fenske NA, Rollison DE. Patterns and timing of sunlight exposure and risk of basal cell and squamous cell carcinomas of the skin--a case-control study. BMC Cancer. 2012 Sep.12:417. Pubmedid: 22994655. Pmcid: PMC3517361.
• Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, Kudchadkar R, Zager J, Gibney G, Sondak VK, Weber J, Mulé JJ, Sarnaik AA. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother. 2012 Oct.35(8):615-620. Pubmedid: 22996367. Pmcid: PMC4467830.
• Han D, Yu D, Zhao X, Marzban SS, Messina JL, Gonzalez RJ, Wayne Cruse C, Sarnaik AA, Puleo C, Sondak VK, Zager JS. Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. Ann Surg Oncol. 2012 Oct.19(11):3335-3342. Pubmedid: 22766986. Pmcid: PMC4504019.
• Sondak VK, Zager JS, Messina JL. Primary tumor thickness as a prognostic factor in Merkel cell carcinoma: the next big thing?. Ann Surg Oncol. 2012 Oct.19(11):3307-3309. Pubmedid: 22825775.
• Gershenwald JE, Coit DG, Sondak VK, Thompson JF. The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. Ann Surg Oncol. 2012 Oct.19(11):3301-3303. Pubmedid: 22868918.
• Leong SP, Mihm MC, Murphy GF, Hoon DS, Kashani-Sabet M, Agarwala SS, Zager JS, Hauschild A, Sondak VK, Guild V, Kirkwood JM. Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastas. 2012 Oct.29(7):775-796. Pubmedid: 22892755. Pmcid: PMC4311146.
• Leong SP, Mihm MC, Murphy GF, Hoon DS, Kashani-Sabet M, Agarwala SS, Zager JS, Hauschild A, Sondak VK, Guild V, Kirkwood JM. Erratum to: Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis. 2012 Oct.29(7):797-799. Pubmedid: 23053741.
• Han D, Zager JS, Han G, Marzban SS, Puleo CA, Sarnaik AA, Reed D, Messina JL, Sondak VK. The unique clinical characteristics of melanoma diagnosed in children. Ann Surg Oncol. 2012 Nov.19(12):3888-3895. Pubmedid: 22864798. Pmcid: PMC4519977.
• Gibney GT, Sondak VK. Extending the reach of BRAF-targeted cancer therapy. Lancet. 2012 May.379(9829):1858-1859. Pubmedid: 22608322.
• Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012 May.18(9):2502-2514. Pubmedid: 22351686. Pmcid: PMC3398738.
• Mills OL, Marzban S, Zager JS, Sondak VK, Messina JL. Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. J Cutan Pathol. 2012 Mar.39(3):331-336. Pubmedid: 22335592.
• Wong JY, Sondak VK. Unanswered questions about margin recommendations for primary cutaneous melanoma. J Natl Compr Canc Ne. 2012 Mar.10(3):357-365. Pubmedid: 22393196.
• Gibney GT, Forsyth PA, Sondak VK. Melanoma in the brain: biology and therapeutic options. Melanoma Res. 2012 Jun.22(3):177-183. Pubmedid: 22495668.
• Sondak VK, Swetter SM, Berwick MA. Gender disparities in patients with melanoma: breaking the glass ceiling. J Clin Oncol. 2012 Jun.30(18):2177-2178. Pubmedid: 22547593.
• Deneve JL, Messina JL, Marzban SS, Gonzalez RJ, Walls BM, Fisher KJ, Ann Chen Y , Wayne Cruse C, Sondak VK, Zager JS. Merkel cell carcinoma of unknown primary origin. Ann Surg Oncol. 2012 Jul.19(7):2360-2366. Pubmedid: 22271206. Pmcid: PMC4504007.
• Rollison DE, Giuliano AR, Messina JL, Fenske NA, Cherpelis BS, Sondak VK, Roetzheim RG, Iannacone MR, Michael KM, Gheit T, Waterboer T, Tommasino M, Pawlita M. Case-control study of Merkel cell polyomavirus infection and cutaneous squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2012 Jan.21(1):74-81. Pubmedid: 22016472. Pmcid: PMC4543303.
• Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Brit J Cancer. 2012 Jan.106(1):85-91. Pubmedid: 22127285. Pmcid: PMC3251861.
• Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK, Kirkwood JM. New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res. 2012 Jan.18(2):336-341. Pubmedid: 22142824. Pmcid: PMC3422891.
• Rollison DE, Iannacone MR, Messina JL, Glass LF, Giuliano AR, Roetzheim RG, Cherpelis BS, Fenske NA, Jonathan KA, Sondak VK. Case-control study of smoking and non-melanoma skin cancer. Cancer Causes Control. 2012 Feb.23(2):245-254. Pubmedid: 22101452.
• Finkelstein SE, Iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, Berman C, Lenox BC, Janssen W, Zager JS, Sondak VK, Letson GD, Antonia SJ, Gabrilovich DI. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients. Int J Radiat Oncol Biol Phys. 2012 Feb.82(2):924-932. Pubmedid: 21398051. Pmcid: PMC4241354.
• Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL, Othus M, Sosman JA, Kirkwood JM, Sondak VK. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res. 2012 Feb.18(4):1129-1137. Pubmedid: 22228638. Pmcid: PMC3481165.
• Tafreshi NK, Huang X, Moberg VE, Barkey NM, Sondak VK, Tian H, Morse DL, Vagner J. Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand. Bioconjug Chem. 2012 Dec.23(12):2451-2459. Pubmedid: 23116461. Pmcid: PMC3563353.
• Iannacone MR, Wang W, Stockwell HG, O'Rourke K, Giuliano AR, Sondak VK, Messina JL, Roetzheim RG, Cherpelis BS, Fenske NA, Michael KM, Waterboer T, Pawlita M, Rollison DE. Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin. J Infect Dis. 2012 Aug.206(3):399-406. Pubmedid: 22661119. Pmcid: PMC4542577.
• Iannacone MR, Gheit T, Waterboer T, Giuliano AR, Messina JL, Fenske NA, Cherpelis BS, Sondak VK, Roetzheim RG, Michael KM, Tommasino M, Pawlita M, Rollison DE. Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev. 2012 Aug.21(8):1303-1313. Pubmedid: 22707711. Pmcid: PMC4543310.
• Knapp CF, Sayegh Z, Schell MJ, Rawal B, Ochoa T, Sondak VK, Messina JL. Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray. Am J Dermatopathxxx. 2012 Aug.34(6):592-596. Pubmedid: 22814318. Pmcid: PMC4634647.
• Howard JH, Thompson JF, Mozzillo N, Nieweg OE, Hoekstra HJ, Roses DF, Sondak VK, Reintgen DS, Kashani-Sabet M, Karakousis CP, Coventry BJ, Kraybill WG, Smithers BM, Elashoff R, Stern SL, Cochran AJ, Faries MB, Morton DL. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol. 2012 Aug.19(8):2547-2555. Pubmedid: 22648554. Pmcid: PMC3405182.
• Chai CY, Zager JS, Szabunio MM, Marzban SS, Chau A, Rossi RM, Sondak VK. Preoperative ultrasound is not useful for identifying nodal metastasis in melanoma patients undergoing sentinel node biopsy: preoperative ultrasound in clinically node-negative melanoma. Ann Surg Oncol. 2012 Apr.19(4):1100-1106. Pubmedid: 22193886. Pmcid: PMC4504035.
• Glass LF, Deconti RC, Sondak VK. Introduction: advanced cutaneous malignancies. Semin Oncol. 2012 Apr.39(2):132-133. Pubmedid: 22484183.
• Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. Melanoma Res. 2012 Apr.22(2):114-122. Pubmedid: 22395415. Pmcid: PMC3303163.
• Sondak VK, Han D, Deneve J, Kudchadkar R. Current and planned multicenter trials for patients with primary or metastatic melanoma. J Surg Oncol. 2011 Sep.104(4):430-437. Pubmedid: 21858839.
• Sondak VK. How do we know when a lymph node dissection is adequate?. Ann Surg Oncol. 2011 Sep.18(9):2419-2421. Pubmedid: 21537859.
• Viscidi RP, Rollison DE, Sondak VK, Silver B, Messina JL, Giuliano AR, Fulp W, Ajidahun A, Rivanera D. Age-specific seroprevalence of Merkel cell polyomavirus, BK virus, and JC virus. Clin Vaccine Immunol. 2011 Oct.18(10):1737-1743. Pubmedid: 21880855. Pmcid: PMC3187023.
• Sosman JA, Moon J, Tuthill RJ, Warneke JA, Vetto JT, Redman BG, Liu PY, Unger JM, Flaherty LE, Sondak VK. A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer. 2011 Oct.117(20):4740-4706. Pubmedid: 21455999. Pmcid: PMC3129414.
• Zager JS, Puleo CA, Sondak VK. What is the significance of the in transit or interval sentinel node in melanoma?. Ann Surg Oncol. 2011 Nov.18(12):3232-3234. Pubmedid: 21837524.
• Balwit JM, Kalinski P, Sondak VK, Coulie PG, Jaffee EM, Gajewski TF, Marincola FM. Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer. J Transl Med. 2011 May.9:60. Pubmedid: 21569425. Pmcid: PMC3115875.
• Daud AI, Xu C, Hwu WJ, Urbas P, Andrews S, Papadopoulos NE, Floren LC, Yver A, Deconti RC, Sondak VK. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma. Cancer Chemother Pharmacol. 2011 Mar.67(3):657-666. Pubmedid: 20509027. Pmcid: PMC3043235.
• Lao CD, Johnson T, Sondak VK, Lowe L, Kim DS, Zhao L, Naftanel M, Olsen S, Brenner DE. Feasibility of serial biopsies of large dysplastic nevi as a melanoma chemoprevention model. J Am Acad Dermatol. 2011 Jun.64(6):1188-1190. Pubmedid: 21571186. Pmcid: PMC3095910.
• Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC, Morton DL, Sondak VK. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011 Jun.29(16):2199-2205. Pubmedid: 21519009. Pmcid: PMC3107741.
• Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Ipilimumab. Nat Rev Drug Discov. 2011 Jun.10(6):411-412. Pubmedid: 21629286.
• Lien MH, Sondak VK. Nonsurgical treatment options for Basal cell carcinoma. J Skin Cancer. 2011 Jul.2011:571734. Pubmedid: 21274437. Pmcid: PMC3025364.
• Sondak VK, Flaherty LE. Targeted therapies: Improved outcomes for patients with metastatic melanoma. Nat Rev Clin Oncol. 2011 Jul.8(9):513-515. Pubmedid: 21788973.
• Sondak VK, Gonzalez RJ, Kudchadkar R. Adjuvant therapy for melanoma: a surgical perspective. Surg Oncol Clin N Am. 2011 Jan.20(1):105-114. Pubmedid: 21111961.
• Rao NG, Yu HH, Trotti A, Sondak VK. The role of radiation therapy in the management of cutaneous melanoma. Surg Oncol Clin N Am. 2011 Jan.20(1):115-131. Pubmedid: 21111962.
• Kudchadkar R, Sondak V. Adjuvant interferon: recommit or move on?. Lancet Oncol. 2011 Feb.12(2):112-113. Pubmedid: 21256808.
• Zager JS, Puleo CA, Sondak VK. Erratum to: What is the Significance of the In Transit or Interval Sentinel Node in Melanoma?. Ann Surg Oncol. 2011 Dec.18 Suppl 3:317-318. Pubmedid: 22048634.
• Sondak VK, Leachman SA. Individualizing follow-up for patients with early-stage melanoma. J Clin Oncol. 2011 Dec.29(35):4606-4608. Pubmedid: 22067394.
• Zager JS, Hochwald SN, Marzban SS, Francois R, Law KM, Davis AH, Messina JL, Vincek V, Mitchell C, Church A, Copeland EM, Sondak VK, Grobmyer SR. Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. J Am Coll Surg. 2011 Apr.212(4):454-460. Pubmedid: 21463767. Pmcid: PMC4505798.
• Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011 Apr.71(7):2750-2760. Pubmedid: 21317224. Pmcid: PMC3070772.
• Sondak VK, Sarnaik AA. Minimizing Morbidity while Preserving Outcome after Inguinal Lymphadenectomy: Navigating between Scylla and Charybdis. Ann Surg Oncol. 2011 Apr.18(4):909-911. Pubmedid: 21246401.
• Gogas H, Kirkwood JM, Falk CS, Dafni U, Sondak VK, Tsoutsos D, Stratigos A, Markopoulos C, Pectasides D, Spyropoulou-Vlachou M. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer. 2010 Sep.116(18):4326-4333. Pubmedid: 20549830. Pmcid: PMC2970916.
• Chu CK, Zager JS, Marzban SS, Gimbel MI, Murray DR, Hestley AC, Messina JL, Sondak VK, Carlson GW, Delman KA. Routine biopsy of Cloquet's node is of limited value in sentinel node positive melanoma patients. J Surg Oncol. 2010 Sep.102(4):315-320. Pubmedid: 20740592.
• Agarwala SS, di Pietro A, Flaherty KT, Garbe C, Grob JJ, Kashani-Sabet M, Kirkwood JM, Leachman S, Messina J, O'Day S, Ribas A, Sondak V. Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct.23(5):e1-e7. Pubmedid: 20718940.
• Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Witter MT, Flaherty LE, Sondak VK. A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). Am J Clin Oncol. 2010 Oct.33(5):495-499. Pubmedid: 20019577. Pmcid: PMC2978644.
• Casper DJ, Ross KI, Messina JL, Sondak VK, Bodden CN, McCardle TW, Frank Glass L. Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma. Am J Dermatopathxxx. 2010 Oct.32(7):650-654. Pubmedid: 20559123.
• DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Brit J Cancer. 2010 Nov.103(10):1548-1553. Pubmedid: 20924376. Pmcid: PMC2990578.
• Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem P. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010 Nov.63(5):751-761. Pubmedid: 20646783. Pmcid: PMC2956767.
• Baldwin BT, Cherpelis BS, Sondak V, Fenske NA. Sentinel lymph node biopsy in melanoma: Facts and controversies. Clin Dermatol. 2010 May.28(3):319-323. Pubmedid: 20541686.
• Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May.28(14):2452-2459. Pubmedid: 20368546. Pmcid: PMC2982783.
• Messina JL, Sondak VK. Refining the criteria for sentinel lymph node biopsy in patients with thinner melanoma: a roadmap for the future. Cancer. 2010 Mar.116(6):1403-1405. Pubmedid: 20091836.
• Sondak VK, Zager JS. Who is to blame for false-negative sentinel node biopsies in melanoma?. Ann Surg Oncol. 2010 Mar.17(3):670-673. Pubmedid: 19953329. Pmcid: PMC2820671.
• Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Brit J Cancer. 2010 Jun.102(12):1724-1730. Pubmedid: 20531415. Pmcid: PMC2883709.
• Kaehler KC, Sondak VK, Schadendorf D, Hauschild A. Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. Eur J Cancer. 2010 Jan.46(1):41-46. Pubmedid: 19857957.
• Sarnaik AA, Zager JS, Cox LE, Ochoa TM, Messina JL, Sondak VK. Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma <= 1 cm is not justified. j clin oncol. 2010 jan.28(1):e7-e7. pubmedid:>19933899.
• Santillan AA, Messina JL, Marzban SS, Crespo G, Sondak VK, Zager JS. Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions. J Clin Oncol. 2010 Jan.28(3):481-486. Pubmedid: 20008627.
• Gonzalez RJ, Padhya TA, Cherpelis BS, Prince MD, Aya-Ay ML, Sondak VK, Cruse CW, Zager JS. The surgical management of primary and metastatic Merkel cell carcinoma. Curr Prob Cancer. 2010 Jan.34(1):77-96. Pubmedid: 20371076.
• Clark JI, Moon J, Hutchins LF, Sosman JA, Kast WM, Da Silva DM, Liu PY, Thompson JA, Flaherty LE, Sondak VK. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. Cancer. 2010 Jan.116(2):424-431. Pubmedid: 19918923. Pmcid: PMC2811758.
• McCardle TW, Sondak VK, Zager J, Messina JL. Merkel cell carcinoma: pathologic findings and prognostic factors. Curr Prob Cancer. 2010 Jan.34(1):47-64. Pubmedid: 20371074.
• Smalley KS, Sondak VK. Melanoma--an unlikely poster child for personalized cancer therapy. N Engl J Med. 2010 Aug.363(9):876-878. Pubmedid: 20818849.
• Farma JM, Ammori JB, Zager JS, Marzban SS, Bui MM, Bichakjian CK, Johnson TM, Lowe L, Sabel MS, Wong SL, Letson GD, Messina JL, Cimmino VM, Sondak VK. Dermatofibrosarcoma protuberans: how wide should we resect?. Ann Surg Oncol. 2010 Aug.17(8):2112-2118. Pubmedid: 20354798.
• Feeney K, Maguire HC, McClay EF, Sato T, Sondak VK, Toporcer M, Zager JS. Surgically unresectable regional melanoma metastases in a patient with renal failure and peripheral vascular disease: are there safe and potentially effective treatments?. Semin Oncol. 2010 Aug.37(4):303-313. Pubmedid: 20816500.
• Gonzalez RJ, Kudchadkar R, Rao NG, Sondak VK. Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma. Ochsner J. 2010.10(2):108-116. Pubmedid: 21603365. Pmcid: PMC3096199.
• Messina J, Möller MG, Sondak VK, Glass FL, Cruse CW. The contoured staged marginal and central surgical excision technique with en face histopathological analysis: useful additions in the armamentarium for treating and diagnosing melanoma in situ. Ann Surg Oncol. 2009 Sep.16(9):2654-2655. Pubmedid: 19588203.
• Agarwala SS, Becker JC, Eggermont AM, Flaherty KT, Garbe C, Goldstein AM, Halpern A, Kashani-Sabet M, Hauschild A, Kirkwood JM, Leachman S, Lorigan P, McMahon M, Messina J, Ribas A, Samlowski WE, Schadendorf D, Sondak VK. Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008. Pigment Cell Melanoma Res. 2009 Oct.22(5):532-543. Pubmedid: 19659612.
• Sondak VK. Nonsentinel node metastases in melanoma: do they reflect the biology of the tumor, the lymph node or the surgeon? : Editorial to Accompany Ghaferi et al., ASO-2009-03-0312.R1. Ann Surg Oncol. 2009 Nov.16(11):2965-2967. Pubmedid: 19669838. Pmcid: PMC2766452.
• Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, Powell B, Ross MI, Sondak VK, Thompson JF. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009 May.60(5):872-875. Pubmedid: 19389531.
• Möller MG, Pappas-Politis E, Zager JS, Santiago LA, Yu D, Prakash A, Kinal A, Clark GS, Zhu W, Puleo CA, Glass LF, Messina JL, Sondak VK, Cruse CW. Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol. 2009 Jun.16(6):1526-1536. Pubmedid: 19050971.
• Raziano RM, Clark GS, Cherpelis BS, Sondak VK, Cruse CW, Fenske NA, Glass LF. Staged margin control techniques for surgical excision of lentigo maligna. G Ital Dermatol Venereol. 2009 Jun.144(3):259-270. Pubmedid: 19528907.
• Phan GQ, Messina JL, Sondak VK, Zager JS. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control. 2009 Jul.16(3):234-239. Pubmedid: 19556963.
• Sarnaik AA, Puleo CA, Zager JS, Sondak VK. Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma. Cancer Control. 2009 Jul.16(3):240-247. Pubmedid: 19556964.
• Santillan AA, Cherpelis BS, Glass LF, Sondak VK. Management of familial melanoma and nonmelanoma skin cancer syndromes. Surg Oncol Clin N Am. 2009 Jan.18(1):73-98, viii. Pubmedid: 19056043.
• McCardle TW, Messina JL, Sondak VK. Completely regressed cutaneous melanocytic lesion revisited. Semin Oncol. 2009 Dec.36(6):498-503. Pubmedid: 19995640.
• Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec.27(36):6199-6206. Pubmedid: 19917835. Pmcid: PMC2793035.
• Sondak VK, Smalley K. Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report. Pigment Cell Melanoma Res. 2009 Aug.22(4):386-387. Pubmedid: 19624312.
• Cantini LP, Meier F, Sondak VK, Smalley KS. The future of targeted therapy approaches in melanoma. Expert Opin Drug Discov. 2009 Apr.4(4):445-456. Pubmedid: 23485043.
• Lien MH, Sondak VK. Diagnostic techniques for primary cutaneous melanoma. G Ital Dermatol Venereol. 2009 Apr.144(2):187-194. Pubmedid: 19357625.
• Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol. 2009 05.24(5):643-650. Pubmedid: 19283671.
• Zager J, Bui M, Farma J, Messina J, Sondak V. Proper margins of excision in dermatofibrosarcoma protuberans: wide or narrow?. Ann Surg Oncol. 2008 Sep.15(9):2614-2616. Pubmedid: 18452044.
• Sondak V. How well are we taking care of melanoma patients in the USA?. Ann Surg Oncol. 2008 Sep.15(9):2360-2362. Pubmedid: 18612692.
• Rollison D, Pawlita M, Giuliano A, Iannacone M, Sondak V, Messina J, Cruse C, Fenske N, Glass L, Kienstra M, Michael K, Waterboer T, Gheit T, Tommasino M. Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers. Int J Cancer. 2008 Nov.123(10):2337-2342. Pubmedid: 18729188.
• Phan GQ, Weber JS, Sondak VK. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues. Ann Surg Oncol. 2008 Nov.15(11):3014-3021. Pubmedid: 18716842.
• Moore S, Persons D, Sosman J, Bobadilla D, Bedell V, Smith D, Wolman S, Tuthill R, Moon J, Sondak V, Slovak M. Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res. 2008 May.14(10):2927-2935. Pubmedid: 18483359.
• Lewis J, Zager J, Yu D, Pelaez D, Riker A, Dessureault S, Cruse C, Reintgen D, Puleo C, Sondak V. Full-thickness grafts procured from skin overlying the sentinel lymph node basin; reconstruction of primary cutaneous malignancy excision defects. Ann Surg Oncol. 2008 Jun.15(6):1733-1740. Pubmedid: 18379848.
• Sondak VK, Flaherty LE. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?. Lancet. 2008 Jul.372(9633):89-90. Pubmedid: 18620932.
• Daud A, Mirza N, Lenox B, Andrews S, Urbas P, Gao G, Lee J, Sondak V, Riker A, Deconti R, Gabrilovich D. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2008 Jul.26(19):3235-3241. Pubmedid: 18591558.
• McLoughlin J, Zager J, Sondak V, Berk L. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control. 2008 Jul.15(3):239-247. Pubmedid: 18596676.
• Shor AC, Agresta SV, D'Amato GZ, Sondak VK. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control. 2008 Jan.15(1):47-54. Pubmedid: 18094660.
• Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb.26(4):527-534. Pubmedid: 18235113.
• Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL, Heller R. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 2008 Dec.26(36):5896-5903. Pubmedid: 19029422. Pmcid: PMC2645111.
• Dissanayake SK, Olkhanud PB, O'Connell MP, Carter A, French AD, Camilli TC, Emeche CD, Hewitt KJ, Rosenthal DT, Leotlela PD, Wade MS, Yang SW, Brant L, Nickoloff BJ, Messina JL, Biragyn A, Hoek KS, Taub DD, Longo DL, Sondak VK, Hewitt SM, Weeraratna AT. Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation. Cancer Res. 2008 Dec.68(24):10205-10214. Pubmedid: 19074888. Pmcid: PMC2605679.
• Melis M, Zager J, Sondak V. Multimodality management of desmoid tumors: how important is a negative surgical margin?. J Surg Oncol. 2008 Dec.98(8):594-602. Pubmedid: 19072851.
• Atkins MB, Hsu J, Lee S, Cohen GI, Flaherty LE, Sosman JA, Sondak VK, Kirkwood JM. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordin. J Clin Oncol. 2008 Dec.26(35):5748-5754. Pubmedid: 19001327. Pmcid: PMC2645104.
• Sondak VK, Messina JL. Lymphangiogenesis: host and tumor factors in nodal metastasis. Arch Dermatol. 2008 Apr.144(4):536-537. Pubmedid: 18427050.
• Sarnaik AA, Zager JS, Sondak VK. Multidisciplinary management of special melanoma situations: oligometastatic disease and bulky nodal sites. Curr Oncol Rep. 2007 Sep.9(5):417-427. Pubmedid: 17706171.
• Feng M, Murphy J, Griffith K, Baker L, Sondak V, Lucas D, McGinn C, RayME. Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys. 2007 Sep.69(1):103-110. Pubmedid: 17560050.
• Hutchins LF, Moon J, Clark JI, Thompson JA, Lange MK, Flaherty LE, Sondak VK. Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer. 2007 Nov.110(10):2269-2275. Pubmedid: 17932881.
• Sondak V, Zager J, Messina J, Thomas J. Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. Clin Adv Hematol Oncol. 2007 Jun.5(6):483-490. Pubmedid: 17679922.
• Blazer DG 3rd, Sondak V, Sabel M. Surgical therapy of cutaneous melanoma. Semin Oncol. 2007 Jun.34(3):270-280. Pubmedid: 17560989.
• McLoughlin J, Zager J, Sondak V. Cytoreductive surgery for melanoma. Surg Oncol Clin N Am. 2007 Jul.16(3):683-693. Pubmedid: 17606201.
• Gogas H, Kirkwood J, Sondak V. Chemotherapy for metastatic melanoma: time for a change?. Cancer. 2007 Feb.109(3):455-464. Pubmedid: 17200963.
• Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S, Yeatman TJ, Sondak VK, Riker AI. Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma. Ann Surg Oncol. 2007 Apr.14(4):1416-1423. Pubmedid: 17195911.
• Sondak V, Messina J. Current status of biomarkers for melanoma metastasis. Idrugs. 2006 Sep.9(9):627-631. Pubmedid: 16952070.
• Becker D, Mihm M, Hewitt S, Sondak V, Fountain J, Thurin M. Markers and tissue resources for melanoma: meeting report. Cancer Res. 2006 Nov.66(22):10652-10657. Pubmedid: 17108101.
• Lao CD, Demierre MF, Sondak VK. Targeting events in melanoma carcinogenesis for the prevention of melanoma. Expert Rev Anticancer Ther. 2006 Nov.6(11):1559-1568. Pubmedid: 17134361.
• Sondak V. Advances in the understanding and treatment of melanoma -- Keystone Symposium. Idrugs. 2006 Mar.9(3):157-160. Pubmedid: 16523374.
• Khan MA, Andrews S, Ismail-Khan R, Munster PN, Brem S, King J, Reintgen DS, Sondak VK, Daud AI. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control. 2006 Jul.13(3):211-217. Pubmedid: 16885917.
• Johnson T, Sondak V, Bichakjian C, Sabel M. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol. 2006 Jan.54(1):19-27. Pubmedid: 16384752.
• Paek S, Griffith K, Johnson T, Sondak V, Wong S, Chang A, Cimmino V, Lowe L, Bradford C, Rees R, Sabel M. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2006 Dec.109(1):100-108. Pubmedid: 17146784.
• Sondak V, Sabel M, Mule J. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?. Clin Cancer Res. 2006 Apr.12(7 Pt 2):2337s-2341s. Pubmedid: 16609055.
• Atkins M, Elder D, Essner R, Flaherty K, Gajewski T, Haluska F, Hwu P, Keilholz U, Kirkwood J, Mier J, Ross M, Slingluff C, Sondak V, Sosman J, Weinstock M, King L. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res. 2006 Apr.12(7 Pt 2):2291s-2296s. Pubmedid: 16609047.
• Johnson T, Sondak V, Bichakjian C, Sabel M. Reply. J Am Acad Dermatol. 2006.55(1):174-175. Pubmedid: 16781324.
• Puleo C, Messina J, Riker A, Glass L, Nelson C, Cruse C, Johnson T, Sondak V. Sentinel node biopsy for thin melanomas: which patients should be considered?. Cancer Control. 2005 Oct.12(4):230-235. Pubmedid: 16258494.
• Demierre M, Sondak V. Chemoprevention of melanoma: theoretical and practical considerations. Cancer Control. 2005 Oct.12(4):219-222. Pubmedid: 16258492.
• Chugh R, Dunn R, Zalupski M, Biermann J, Sondak V, Mace J, Leu K, Chandler W, Baker L. Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. J Clin Oncol. 2005 May.23(15):3597-3604. Pubmedid: 15908670.
• Demierre M, Sondak V. Cutaneous melanoma: pathogenesis and rationale for chemoprevention. Crit Rev Oncol Hematol. 2005 Mar.53(3):225-239. Pubmedid: 15718148.
• Sabel M, Griffith K, Sondak V, Lowe L, Schwartz J, Cimmino V, Chang A, Rees R, Bradford C, Johnson T. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005 Jul.201(1):37-47. Pubmedid: 15978442.
• Worden F, Taylor J, Biermann J, Sondak V, Leu K, Chugh R, McGinn C, Zalupski M, Baker L. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol. 2005 Jan.23(1):105-112. Pubmedid: 15625365.
• Thomas DG, Giordano TJ, Sanders D, Biermann S, Sondak VK, Trent JC, Yu D, Pollock RE, Baker L. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer. 2005 Feb.103(4):830-838. Pubmedid: 15641030.
• Francis IR, Cohan RH, Varma DG, Sondak VK. Retroperitoneal sarcomas. Cancer Imaging. 2005 Aug.5:89-94. Pubmedid: 16154826. Pmcid: PMC1665230.
• Daud A, Sondak V. Melanoma: changes below the surface. Cancer Control. 2005.12(4):217-218. Pubmedid: 16258491.
• Wang T, Johnson T, Cascade P, Redman B, Sondak V, Schwartz J. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol. 2004 Sep.51(3):399-405. Pubmedid: 15337983.
• Chung ES, Sabel MS, Sondak VK. Current state of treatment for primary cutaneous melanoma. Clin Exp Med. 2004 Oct.4(2):65-77. Pubmedid: 15672943.
• Karimipour DJ, Lowe L, Su L, Hamilton T, Sondak V, Johnson TM, Fullen D. Standard immunostains for melanoma in sentinel lymph node specimens: which ones are most useful?. J Am Acad Dermatol. 2004 May.50(5):759-764. Pubmedid: 15097961.
• Leu K, Ostruszka L, Shewach D, Zalupski M, Sondak V, Biermann J, Lee J, Couwlier C, Palazzolo K, Baker L. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004 May.22(9):1706-1712. Pubmedid: 15117993.
• Sondak V, Taylor J, Sabel M, Wang Y, Lowe L, Grover A, Chang A, Yahanda A, Moon J, Johnson T. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004 Mar.11(3):247-258. Pubmedid: 14993019.
• Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004 Mar.10(5):1670-1677. Pubmedid: 15014018.
• Tang H, Qian D, Sondak V, Stachura S, Lin J. A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin. Brit J Cancer. 2004 Mar.90(6):1285-1292. Pubmedid: 15026814. Pmcid: PMC2409661.
• Sabel MS, Sondak VK. Point: Interferon-alpha for adjuvant therapy for melanoma patients. J Natl Compr Canc Ne. 2004 Jan.2(1):61-68. Pubmedid: 19777695.
• Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, Tchekmedyian NS, Sondak VK. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer. 2004 Apr.100(8):1699-1704. Pubmedid: 15073859.
• Song H, Sondak VK, Barber DL, Reid TJ, Lin J. Modulation of Janus kinase 2 by cisplatin in cancer cells. Int J Oncol. 2004 Apr.24(4):1017-1026. Pubmedid: 15010843.
• Sosman J, Weeraratna A, Sondak V. When will melanoma vaccines be proven effective. J Clin Oncol. 2004.22(3):387-389. Pubmedid: 14691126.
• Johnson T, Bradford C, Gruber S, Sondak V, Schwartz J. Staging workup, sentinel node biopsy, and follow-up tests for melanoma: update of current concepts. Arch Dermatol. 2004.140(1):107-113. Pubmedid: 14732667.
• Johnson T, Sondak V. Melanoma margins: the importance and need for more evidence-based trials. Arch Dermatol. 2004.140(9):1148-1150. Pubmedid: 15381557.
• Su L, Fullen D, Lowe L, Wang T, Schwartz J, Cimmino V, Sondak V, Johnson T. Desmoplastic and neurotropic melanoma. Cancer. 2004.100(3):598-604. Pubmedid: 14745878.
• Douglas J, Sondak V. RE: A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest. 2004.22(4):643-644. Pubmedid: 15565821.
• Pawlik TM, Paulino AF, McGinn CJ, Baker LH, Cohen DS, Morris JS, Rees R, Sondak VK. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003 Oct.98(8):1716-1726. Pubmedid: 14534889.
• Blazer DG 3rd, Sabel M, Sondak V. Is there a role for sentinel lymph node biopsy in the management of sarcoma?. Surg Oncol. 2003 Nov.12(3):201-206. Pubmedid: 12957624.
• Pawlik T, Sondak V. Malignant melanoma: current state of primary and adjuvant treatment. Crit Rev Oncol Hematol. 2003 Mar.45(3):245-264. Pubmedid: 12633838.
• Terando A, Sabel MS, Sondak VK. Melanoma: adjuvant therapy and other treatment options. CURR TREAT OPTION ON. 2003 Jun.4(3):187-199. Pubmedid: 12718796.
• Su L, Fullen D, Sondak V, Johnson T, Lowe L. Sentinel lymph node biopsy for patients with problematic spitzoid melanocytic lesions: a report on 18 patients. Cancer. 2003 Jan.97(2):499-507. Pubmedid: 12518375.
• Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 2003 Jan.97(1):186-200. Pubmedid: 12491520.
• Wagner J, Sondak V. The sentinel lymph node: more than just another blue lymph node. Cancer. 2003 Apr.97(8):1821-1823. Pubmedid: 12673706.
• Bogner P, Fullen D, Lowe L, Paulino A, Biermann J, Sondak V, Su L. Lymphatic mapping and sentinel lymph node biopsy in the detection of early metastasis from sweat gland carcinoma. Cancer. 2003.97(9):2285-2289. Pubmedid: 12712485.
• Sabel MS, Sondak VK. Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma?. Drugs. 2003.63(11):1053-1058. Pubmedid: 12749732.
• Sondak V, Sosman J. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol. 2003.13(6):409-415. Pubmedid: 15001159.
• Sabel M, Sondak V. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist. 2003.8(5):451-458. Pubmedid: 14530498.
• Sosman J, Sondak V. Melacine: an allogeneic melanoma tumor cell lysate vaccine. Expert Rev Vaccines. 2003.2(3):353-368. Pubmedid: 12903801.
• Sondak VK. How does interferon work? Does it even matter?. Cancer. 2002 Sep.95(5):947-949. Pubmedid: 12209676.
• Sondak VK, Chang AE. Melanoma and human leukocyte antigen status: the missing link?. Ann Surg Oncol. 2002 Oct.9(8):723-724. Pubmedid: 12374654.
• Kirkwood J, Ibrahim J, Sondak V, Ernstoff M, Flaherty L, Haluska F. Use and abuse of statistics in evidence-based medicine. J Clin Oncol. 2002 Oct.20(19):4122-4123. Pubmedid: 12351612.
• Tuthill R, Unger J, Liu P, Flaherty L, Sondak V. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol. 2002 Oct.118(4):504-511. Pubmedid: 12375635.
• Su L, Lowe L, Bradford C, Yahanda A, Johnson T, Sondak V. Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes. J Am Acad Dermatol. 2002 May.46(5):661-666. Pubmedid: 12004304.
• Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M. Interferon alfa-2a for melanoma metastases. Lancet. 2002 Mar.359(9310):978-979. Pubmedid: 11918944.
• Whitehead R, Unger J, Flaherty L, Kraut E, Mills G, Klein C, ChapmanRA, Doolittle G, Hammond N, Sondak V. A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study. Invest New Drugs. 2002 Feb.20(1):105-111. Pubmedid: 12003185.
• Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, Baker L. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer. 2002 Dec.95(11):2373-2379. Pubmedid: 12436445.
• Sosman J, Unger J, Liu P, Flaherty L, Park M, Kempf R, Thompson J, Terasaki P, Sondak V. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol. 2002 Apr.20(8):2067-2075. Pubmedid: 11956267.
• Sondak V, Liu P, Tuthill R, Kempf R, Unger J, Sosman J, Thompson J, Weiss G, Redman B, Jakowatz J, Noyes R, Flaherty L. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002 Apr.20(8):2058-2066. Pubmedid: 11956266.
• Sabel M, Sondak V. Melanoma vaccines: breakthrough or bust?. Cancer Invest. 2002.20(7-8):1114-1116. Pubmedid: 12449744.
• Sabel M, Sondak V. Tumor vaccines: a role in preventing recurrence in melanoma?. Am J Clin Dermatol. 2002.3(9):609-616. Pubmedid: 12444803.
• Schwartz J, Wang T, Hamilton T, Lowe L, Sondak V, Johnson T. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer. 2002.95(7):1562-1568. Pubmedid: 12237926.
• Sondak VK. Use of adjuvant therapy in cutaneous melanoma. Expert Rev Anticancer Ther. 2001 Oct.1(3):421-426. Pubmedid: 12113108.
• Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May.19(9):2370-2380. Pubmedid: 11331315.
• Unger JM, Flaherty LE, Liu PY, Albain KS, Sondak VK. Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials. Cancer. 2001 Mar.91(6):1148-1155. Pubmedid: 11267960.
• Sondak VK, Ross MI, Schuchter LM. Early stage (I, II, III) melanoma. CURR TREAT OPTION ON. 2001 Jun.2(3):183-191. Pubmedid: 12057118.
• Whitehead RP, Unger JM, Flaherty LE, Eckardt JR, Taylor SA, Didolkar MS, Samlowski W, Sondak VK. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study. Invest New Drugs. 2001.19(3):239-243. Pubmedid: 11561681.
• Lin J, Jin X, Page C, Sondak VK, Jiang G, Reynolds RK. A modified p53 overcomes mdm2-mediated oncogenic transformation: a potential cancer therapeutic agent. Cancer Res. 2000 Oct.60(20):5895-5901. Pubmedid: 11059788.
• Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun.18(12):2444-2458. Pubmedid: 10856105.
• Brewer GJ, Dick RD, Grover DK, LeClaire V, Tseng M, Wicha M, Pienta K, Redman BG, Jahan T, Sondak VK, Strawderman M, LeCarpentier G, Merajver SD. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. Clin Cancer Res. 2000 Jan.6(1):1-10. Pubmedid: 10656425.
• Gupta AK, Cohan RH, Francis IR, Sondak VK, Korobkin M. CT of recurrent retroperitoneal sarcomas. Ajr Am J Roentgenol. 2000 Apr.174(4):1025-1030. Pubmedid: 10749244.
• Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol. 1999 Oct.17(10):3313-3323. Pubmedid: 10506635.
• Margolin KA, Liu PY, Unger JM, Fletcher WS, Flaherty LE, Urba WJ, Hersh EM, Hutchins LE, Sosman JA, Smith JW, Weiss GR, Sondak VK. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial. J Cancer Res Clin Oncol. 1999 Jun.125(5):292-296. Pubmedid: 10359134.
• McMasters KM, Sondak VK, Lotze MT, Ross MI. Recent advances in melanoma staging and therapy. Ann Surg Oncol. 1999 Jul.6(5):467-475. Pubmedid: 10458685.
• Sondak VK, Cimmino VM, Lowe LM, Dubay DA, Johnson TM. Dermatofibrosarcoma protuberans: what is the best surgical approach?. Surg Oncol. 1999 Dec.8(4):183-189. Pubmedid: 11128831.
• Johnson TM, Yahanda AM, Chang AE, Fader DJ, Sondak VK. Advances in melanoma therapy. J Am Acad Dermatol. 1998 May.38(5 Pt 1):731-741. Pubmedid: 9591818.
• Sondak VK, Robertson JM, Sussman JJ, Saran PA, Chang AE, Lawrence TS. Preoperative idoxuridine and radiation for large soft tissue sarcomas: clinical results with five-year follow-up. Ann Surg Oncol. 1998 Mar.5(2):106-112. Pubmedid: 9527262.
• Margolin KA, Liu PY, Flaherty LE, Sosman JA, Walker MJ, Smith JW, Fletcher WS, Weiss GR, Unger JM, Sondak VK. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol. 1998 Feb.16(2):664-669. Pubmedid: 9469356.
• Flaherty LE, Unger JM, Liu PY, Mertens WC, Sondak VK. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol. 1998 Dec.21(6):568-572. Pubmedid: 9856657.
• Wang TS, Lowe L, Smith JW, Francis IR, Sondak VK, Dworzanian L, Finkelstein S, Slingluff CL, Johnson TM. Complete spontaneous regression of pulmonary metastatic melanoma. Dermatol Surg. 1998 Aug.24(8):915-919. Pubmedid: 9723062.
• Fig LM, Brown RS, von Moll L, Appelman HD, Stevens R, Harness J, August D, Sondak VK, Chang AE, Zasadny KR, Fisher SJ, Johnson JW, Wicha MS, Colcher D, Lichter AS, Wahl RL. Immunolymphoscintigraphy in breast cancer: evaluation using 131I-labeled monoclonal antibody B72.3. Nucl Med Biol. 1998 Apr.25(3):251-260. Pubmedid: 9620631.
• Ratner D, Thomas CO, Johnson TM, Sondak VK, Hamilton TA, Nelson BR, Swanson NA, Garcia C, Clark RE, Grande DJ. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans. Results of a multiinstitutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol. 1997 Oct.37(4):600-613. Pubmedid: 9344201.
• Basler GC, Fader DJ, Yahanda A, Sondak VK, Johnson TM. The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. J Am Acad Dermatol. 1997 Mar.36(3 Pt 1):403-408. Pubmedid: 9091471.
• Sondak VK, Wolfe JA. Adjuvant therapy for melanoma. Curr Opin Oncol. 1997 Mar.9(2):189-204. Pubmedid: 9161800.
• Durand-Zaleski I, Roche B, Buyse M, Carlson R, O'Connell MJ, Rougier P, Chang AE, Sondak VK, Kemeny MM, Allen-Mersh TG, Fagniez PL, Le Bourgeois JP, Piedbois P. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases. Meta-Analysis Group in Cancer. J Natl Cancer Inst. 1997 Jun.89(11):790-795. Pubmedid: 9182977.
• Johnson TM, Fader DJ, Chang AE, Yahanda A, Smith JW, Hamlet KR, Sondak VK. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol. 1997 Jul.4(5):396-402. Pubmedid: 9259966.
• Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol. 1997 Feb.15(2):796-807. Pubmedid: 9053507.
• Sondak VK. Multi-institutional melanoma vaccine trial. Ann Surg Oncol. 1996 Nov.3(6):588-589. Pubmedid: 8915494.
• Flaherty LE, Liu PY, Mitchell MS, Fletcher WS, Walker MJ, Goodwin JW, Stephens RL, Sondak VK. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921). Am J Clin Oncol. 1996 Apr.19(2):108-113. Pubmedid: 8610631.
• Johnson TM, Sondak VK. A centimeter here, a centimeter there: does it matter?. J Am Acad Dermatol. 1995 Sep.33(3):532-534. Pubmedid: 7657884.
• Fortin PT, Freiberg AA, Rees R, Sondak VK, Johnson TM. Malignant melanoma of the foot and ankle. J Bone Joint Surg Am. 1995 Sep.77(9):1396-1403. Pubmedid: 7673291.
• Meyskens FL, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst. 1995 Nov.87(22):1710-1713. Pubmedid: 7473820.
• Robertson JM, Sondak VK, Weiss SA, Sussman JJ, Chang AE, Lawrence TS. Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 1995 Jan.31(1):87-92. Pubmedid: 7995772.
• Slavik M, Liu PY, Kraut EH, Natale RB, Flaherty LE, Sondak VK. Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study. Invest New Drugs. 1995.13(2):143-147. Pubmedid: 8617577.
• Arca MJ, Sondak VK, Chang AE. Diagnostic procedures and pretreatment evaluation of soft tissue sarcomas. Semin Surg Oncol. 1994 Sep.10(5):323-331. Pubmedid: 7997726.
• Meyskens FL, Liu PY, Tuthill RJ, Sondak VK, Fletcher WS, Jewell WR, Samlowski W, Balcerzak SP, Rector DJ, Noyes RD. Randomized trial of vitamin A versus observation as adjuvant therapy in high-risk primary malignant melanoma: a Southwest Oncology Group study. J Clin Oncol. 1994 Oct.12(10):2060-2065. Pubmedid: 7931474.
• Sussman JJ, Shu S, Sondak VK, Chang AE. Activation of T lymphocytes for the adoptive immunotherapy of cancer. Ann Surg Oncol. 1994 Jul.1(4):296-306. Pubmedid: 7850528.
• Hammel JM, Tuck MK, Hain JM, Chang AE, Sondak VK. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy. J Immunother Emphasis Tumor Immunol. 1994 Jul.16(1):1-12. Pubmedid: 8081555.
• August DA, Rea T, Sondak VK. Age-related differences in breast cancer treatment. Ann Surg Oncol. 1994 Jan.1(1):45-52. Pubmedid: 7834427.
• Sondak VK, Kopecky KJ, Liu PY, Fletcher WS, Harvey WH, Laufman LR. Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group. Anticancer Drugs. 1994 Apr.5(2):147-150. Pubmedid: 8049497.
• Chang AE, Geiger JD, Sondak VK, Shu S. Adoptive cellular therapy of malignancy. Arch Surg. 1993 Nov.128(11):1281-1290. Pubmedid: 8239992.
• Chang AE, Yoshizawa H, Sakai K, Cameron MJ, Sondak VK, Shu S. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 1993 Mar.53(5):1043-1050. Pubmedid: 8439951.
• Sondak VK, Lawrence TS. Preoperative multimodality treatment of large soft tissue sarcomas. How can we get more (function) from less (surgery)?. Cancer. 1993 Jun.71(11):3469-3471. Pubmedid: 8490897.
• Fletcher WS, Daniels DS, Sondak VK, Dana B, Townsend R, Hynes HE, Hutchins LF, Pancoast JR. Evaluation of cisplatin and DTIC in inoperable stage III and IV melanoma. A Southwest Oncology Group study. Am J Clin Oncol. 1993 Aug.16(4):359-362. Pubmedid: 8328416.
• Flaherty LE, Liu PY, Fletcher WS, Goodwin JW, Balcerzak SP, Daniels D, Stephens RL, Sondak VK. Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trial. J Natl Cancer Inst. 1992 Jun.84(11):893-894. Pubmedid: 1593656.
• Sondak VK, Wagner PD, Shu S, Chang AE. Suppressive effects of visceral tumor on the generation of antitumor T cells for adoptive immunotherapy. Arch Surg. 1991 Apr.126(4):442-446. Pubmedid: 2009059.
• Sondak VK, Economou JS, Eilber FR. Soft tissue sarcomas of the extremity and retroperitoneum: advances in management. Adv Surg. 1991.24:333-359. Pubmedid: 1996527.
• Sondak VK, Korn EL, Kern DH. In vitro testing of chemotherapeutic combinations in a rapid thymidine incorporation assay. Int J Cell Cloning. 1988 Nov.6(6):378-391. Pubmedid: 3230328.
• Sondak VK, Hildebrand-Zanki SU, Butler A, Kern DH. Growth inhibitory effect of sodium azide in chemosensitivity assays. Int J Cell Cloning. 1987 May.5(3):191-201. Pubmedid: 2439615.
• Kern DH, Chien FW, Goodwein SN, Sondak VK. Effects of hormonal growth factors on colony formation and chemosensitivity of human tumors in agarose. In Vitro Cell Dev Biol. 1987 Dec.23(12):863-866. Pubmedid: 3320016.
• Kern DH, Sondak VK, Morgan CR, Hildebrand-Zanki SU. Clinical application of the thymidine incorporation assay. Ann Clin Lab Sci. 1987.17(6):383-388. Pubmedid: 3688821.
• Korn EL, Sondak VK, Bertelsen CA, Kern DH. Analysis of the clinical utility of a predictive chemosensitivity assay. Stat Med. 1985 Oct.4(4):527-534. Pubmedid: 2418477.
• Kern DH, Drogemuller CR, Kennedy MC, Hildebrand-Zanki SU, Tanigawa N, Sondak VK. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res. 1985 Nov.45(11 Pt 1):5436-5441. Pubmedid: 4053017.
• Sondak VK, Bertelsen CA, Kern DH, Morton DL. Evolution and clinical application of a rapid chemosensitivity assay. Cancer. 1985 Mar.55(6):1367-1371. Pubmedid: 3971305.
• Sondak VK, Bertelsen CA, Giuliano AE, Morton DL, Kern DH. In vitro sensitivity of breast carcinoma to combination chemotherapy. Curr Surg. 1984 Nov.41(6):470-472. Pubmedid: 6518815.
• Bertelsen CA, Sondak VK, Mann BD, Korn EL, Kern DH. Chemosensitivity testing of human solid tumors. A review of 1582 assays with 258 clinical correlations. Cancer. 1984 Mar.53(6):1240-1245. Pubmedid: 6692313.
• Sondak VK, Bertelsen CA, Tanigawa N, Hildebrand-Zanki SU, Morton DL, Korn EL, Kern DH. Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res. 1984 Apr.44(4):1725-1728. Pubmedid: 6704978.
• Kudchadkar RR, Smalley KS, Glass LF, Trimble JS, Sondak VK. Targeted therapy in melanoma. Clin Dermatol. 31(2):200-208. Pubmedid: 23438383.
• Riker A, Glass F, Perez I, Cruse C, Messina J, Sondak V. Cutaneous melanoma: methods of biopsy and definitive surgical excision. Dermatol Ther. 18(5):387-393. Pubmedid: 16297013.
• Sondak VK, Liu PY, Flaherty LE, Fletcher WS, Periman P, Gandara DR, Taylor SA, Balcerzak SP, Meyskens FL. A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study. Cancer J Sci Am. 5(1):41-47. Pubmedid: 10188060.
• Sondak VK, Flaherty LE. Adjuvant high-dose interferon revisited. Cancer J. 6(3):132-134. Pubmedid: 10882326.